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Clostridium difficile is a gram-positive, spore-forming, anaerobic, nosocomial pathogen
affecting hospitalized patients taking long-term antibiotics. The bacterium is responsible for over
500,000 cases and 29,000 deaths annually (Lessa et al., 2015), with ~ $3 billion in health-care
costs (O'Brien et al., 2007). There has been the emergence of a new hypervirulent strain of C.
difficile known as North American Pulsotype 1 (NAP1), which is responsible for severe infections.
Further, an increase in the incidence of C. difficile infections outside of hospital environments
(Hensgens et al., 2012; McDonald et al., 2006; Rupnik et al., 2009) is observed. It is reported that
32% of all C. difficile illnesses in the United States are community associated C. difficile infections,
especially in individuals with no recent hospitalization (Lessa, 2013). C. difficile has been isolated
widely from the environment in many countries, especially from soil and water. The persistence
of C. difficile in the environment and isolation of hypervirulent C. difficile from food animals and
foods suggest a potential role for foods as a source of C. difficile infection in the community.
In this dissertation, the prevalence of C. difficile in ready-to-eat lettuce collected from retail
stores in Connecticut was investigated. The results showed a prevalence rate of 23% in ready-toeat lettuce, with the isolates being toxigenic and resistant to multiple antibiotics. The survival of
C. difficile in ready-to-eat lettuce bags packaged with modified atmosphere packaging (MAP)
conditions was also studied. C. difficile spores were found to remain viable under MAP, but did
not increase in number over 10 days of refrigerated storage.
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As the second objective, the viability of C. difficile spores in ground beef subjected to
chilling, freezing and cooking was investigated. Results revealed that chilling for a week or
freezing for 12 weeks did not affect the survival of C. difficile spores (p > 0.05). Moreover, cooking
ground beef to the USDA recommended internal temperature (71.1°C) decreased spore counts
only by 1 log CFU/g compared to uncooked controls.
Since no previous research investigated the viability of C. difficile spores in any fermented
meat product, the effect of acidity (fermentation) and cooking on the viability of C. difficile spores
in ready-to-eat, fermented pork summer sausage over a period of 60 days at 4oC was determined.
Results indicated that C. difficile spores can survive the acidity and cooking in fermented pork
summer sausage, underscoring the need for effective intervention strategies to control C. difficile
contamination of pork carcasses.
C. difficile spores can persist on hospital surfaces and equipment for prolonged periods of
time, thereby serving as a potential source of infection. Commonly contaminated hospital
surfaces and equipment include, floors, toilets, windowsills, bedrails, bedside-tables,
thermometers, blood-pressure cuffs, and intravenous catheters (Dubberke et al., 2008; Gerding et
al., 2008; Guerrero et al., 2012). C. difficile spores are resistant to most of the commonly used
physical and chemical disinfectants, including household dilutions of sodium hypochlorite
(Edwards et al., 2016; Fawley et al., 2007; Gerding et al., 2008). Moreover, sodium hypochlorite
is not suitable for sanitizing some medical surfaces and devices. Therefore, as the fourth
objective, the efficacy of a novel disinfectant, namely octenidine hydrochloride (OH), for
reducing C. difficile spores on stainless steel surfaces was evaluated. Application of OH (5%)
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directly on stainless steel surfaces or wiping with OH decreased populations of C. difficile spores
significantly compared to controls.
In infected humans, sporulation of C. difficile vegetative cells occurs in the colon, and
newly formed spores shed in the feces can potentially contaminate hospitals and healthcare
facilities, leading to new infections through the fecal-oral route (Barbut, Menuet et al. 2009).
Therefore, it is critical to control C. difficile sporulation in the human gastrointestinal tract for
controlling the infection and its transmission. Aspirin (acetylsalicylic acid) is a non-steroidal antiinflammatory drug widely used in medicine (Soni 2005). In an observational study of adults
diagnosed with C. difficile infection, aspirin was identified as a factor that reduced mortality
(Saliba, Barnett-Griness et al. 2014), although the mechanism behind this is not known. Therefore,
as the final objective, the effect of aspirin on C. difficile toxin production, spore production, spore
germination and spore outgrowth was investigated. Although aspirin had no effect on C. difficile
toxin production, it reduced spore production and spore outgrowth significantly in C. difficile (p <
0.05). Results justify follow-up studies in an appropriate animal model to validate the antisporulation effect of aspirin against C. difficile.
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Chapter I
Introduction

1

Clostridium difficile is an anaerobic, spore-forming bacterium, which is transmitted
through the fecal-oral route. C. difficile infection (CDI) can be mild to life-threatening, and
outbreaks are predominantly observed in healthcare settings (Stanley et al., 2013; Weese, 2010).
In the United States, over 500,000 cases of CDI are reported each year, costing the economy an
estimated 3 billion for treatment (Ghose et al., 2007; Lessa et al., 2015). Although toxins are the
major virulence factors responsible for the pathogenesis of C. difficile infection, sporulation, spore
germination and spore outgrowth are critical for transmission and relapse of CDI (Akerlund et al.,
2008; Hookman & Barkin, 2009; Sunenshine & McDonald, 2006). Transmission of C. difficile
spores occurs through shedding in the feces of infected individuals and asymptomatic carriers,
which leads to contamination of the hospital environment (Riggs et al., 2007; Weber et al., 2010).
Relapse of CDI is a major concern, and is observed in 20-30% of reported cases with risk
increasing to 60% after 2 or more recurrences (Barbut et al., 2000; Kelly & LaMont, 2008; Louie
et al., 2011). Moreover, CDI patients can shed C. difficile spores for up to four weeks post recovery
(Sethi et al., 2010).
C. difficile spores can survive in the abiotic environment such as on hospital surfaces and
equipment for up to 5 months, thereby serving as a potential source of infection. In addition,
spores are resistant to most of the commonly used physical and chemical disinfectants, including
household dilutions of sodium hypochlorite (Edwards et al., 2016; Fawley et al., 2007; Gerding
et al., 2008). A ten percent solution of bleach is effective against C. difficile spores (Edwards et
al., 2016), but it is not recommended for routine use due to its potential to cause respiratory
distress in healthcare workers and patients, and corrosion on hospital equipment (Keward, 2013).
Therefore, there is a need for safe and effective disinfectants, which can be used routinely to
reduce CDI transmission in hospitals.

2

Susceptible individuals undergoing long-term antibiotic therapy have disrupted gut
microbial flora, which provides an opportune environment for C. difficile spores to germinate
and cause infection (Evans & Safdar, 2015; Sun et al., 2011). C. difficile spores germinate in the
intestine, where bile acid acts as a germinant, and vegetative cells produce toxins in the colon,
leading to severe diarrhea. In addition, sporulation of vegetative cells occurs in the colon, which
produce new spores that are shed in the feces to continue the infectious cycle. However, C.
difficile transmission and relapse can be prevented by intervening with C. difficile sporulation,
germination and/or outgrowth.
Although C. difficile is acquired primarily from nosocomial settings, there has been an
increase in community-associated C. difficile infections (CA-CDI), especially in low risk
individuals outside of hospital settings. Community-associated infections occur in the
community in individuals with no hospitalization within the past 12 weeks or infections that
occur within 48 h of hospital admission (Lessa, 2013). Community-associated infections now
account for 32% of all CDI cases, suggesting the possibility of an additional C. difficile source
that can cause CDI in non-hospitalized patients (Hensgens et al., 2012; Lessa, 2013; McDonald
et al., 2006; Rupnik et al., 2009). C. difficile is widely detected in the gut of most domestic and
wild animals, including pets (Álvarez‐Pérez et al., 2015; Himsworth et al., 2014; Medina-Torres
et al., 2011). Shedding of C. difficile spores in the feces of infected or asymptomatic carrier
animals has been identified as a source of environmental contamination (Rodriguez-Palacios et
al., 2006; Rodriguez-Palacios et al., 2014b). Research in several countries has identified the
presence of C. difficile spores in a variety of food animals, meat, water, and the environment
(Bakri et al., 2009; Costa et al., 2012; Houser et al., 2011; Thitaram et al., 2016; Xu et al., 2014).
However, the effect of refrigeration, freezing, cooking and acidity on the viability of C. difficile
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spores in meat products has not been investigated. In addition, limited information exists on the
the prevalence of C. difficile in fresh produce in the US. Although researchers in Europe have
isolated C. difficile in ready-to-eat lettuce (Bakri et al., 2009; Eckert et al., 2013), US data are
limited to a single publication in vegetables (Rodriguez-Palacios et al., 2014a). Potential
contamination of fresh produce with C. difficile spores from soil, water and animal waste in
agricultural fields, along with the absence of cooking before consumption, increase the
foodborne disease risk associated with C. difficile in fresh produce.
Hypothesis:
Foods such as ready-to-eat lettuce are a potential source of multi-drug resistant C.
difficile spores. In addition, C. difficile spores can survive chilling, freezing and cooking
temperatures in meat products such as ground beef, and can withstand the high acidity and
cooking in ready-to-eat fermented products such as summer sausage. Further, the new generation
disinfectant, octenidine dihydrochloride, is effective in killing C. difficile spores on stainless
steel surfaces, whereas the commonly prescribed, non-steroidal anti-inflammatory drug, aspirin,
exerts potent anti-sporulation effects against C. difficile.
The specific objectives of this dissertation are to:
1. Determine the prevalence of C. difficile in ready-to-eat lettuce (REL) in Connecticut, and
study the effect of modified atmosphere packaging (MAP) on the viability of C. difficile spores
in REL.
2. Determine the effect of chilling, freezing and cooking on the viability of C. difficile spores in
ground beef.
3. Study the effect of acidity and cooking on the viability of C. difficile spores in fermented pork
summer sausage.
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4. Determine the efficacy of octenidine hydrochloride (OH) in reducing C. difficile spores on
stainless steel surfaces.
5. Investigate the effect of acetylsalicylic acid (aspirin) on C. difficile sporulation and spore
germination in vitro.
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Chapter II
Review of Literature
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Clostridium difficile is a spore-forming anaerobic bacterium which causes a
serious toxin-mediated infection in the gastrointestinal tract (Hookman & Barkin, 2009; Smits et
al., 2016). The mild symptoms of the disease include fever and abdominal pain, and more severe
infections lead to toxic megacolon, sepsis and shock (Rupnik et al., 2009). Some infected
individuals do not show symptoms but play a role in C. difficile transmission, and are classified as
asymptomatic carriers (Galdys et al., 2014; Hensgens et al., 2012). A study on the incidence of C.
difficile in a healthy human population in Pennsylvania found a carriage rate of 6.6% underscoring
the potential for asymptomatic carriers to be a reservoir for C. difficile (Galdys et al., 2014). There
has been a rise in community-associated CDI in individuals without the common risk factors of
antibiotic therapy, recent healthcare exposure or advanced age (Dumyati et al., 2012; Lessa, 2013).
The increase in community-associated C. difficile infection (CDI) along with the isolation of C.
difficile isolates in animals and the environment suggests that food could be a potential source for
community-associated human infections.

1. Morphology and biochemical characteristics
Clostridium difficile is an anaerobic bacillus measuring 3-5 µm in length. During stationary
phase after 72 h of growth, terminal spores bulging from one end of the bacillus can be visualized
with Gram staining (Postma et al., 2015). Flagella allow motility of C. difficile, but the role played
by flagella in adherence to the host mucosa is unclear. However, studies involving C. difficile
mutants, lacking flagella-building components showed increased adherence of the bacterium to
cells (Janoir, 2015). C. difficile can be grown in non-selective microbiological media such as brain
heart infusion (BHI) or blood based media for pure culture experiments. The bacterium is a strict
anaerobe, which grows optimally under the gaseous conditions of 80% nitrogen, 10% carbon
dioxide and 10% hydrogen at 37°C. C. difficile colonies are flat, non-hemolytic, range from opaque
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to milky white in color, and most often have irregularly shaped edges resembling a fried egg shape
(Wren, 2010). Colonies have a characteristic horse manure smell, which is a preliminary
identification characteristic of C. difficile (Delmée, 2001). To enhance growth, sodium
taurocholate can be added to the medium, which improves germination and sporulation of C.
difficile (Wren, 2010). For the detection of C. difficile in prevalence studies, selective media such
as Clostridium difficile moxalactam norfloxacin (CDMN) broth containing selective antibiotics
and 7% horse blood can be used (Mooyottu et al., 2015). An L-Proline-Aminopeptidase test can
be used along with selective media for initial identification of C. difficile. The L-prolineaminopeptidase uses p-dimethylaminocinnamaldehyde as the substrate, and produces a dark pink
color in the presence of -proline-beta-naphthylamide, thereby suggesting C. difficile (Fedorko &
Williams, 1997). C. difficile produces spores, which are highly resistant to high temperature,
desiccation, nutrient deprivation and other environmental stresses.

2. Epidemiology of C. difficile
Annually in the US, an estimated 500,000 cases of CDI are reported, which results in ~ $3 billion
as healthcare and treatment costs (Lessa et al., 2015). In the last decade, CDI has become more
difficult to treat as a result of increased resistance to antibiotics and from the emergence of new
hypervirulent strains (Postma et al., 2015; Valiente et al., 2014; Zhanel et al., 2015). A strain
known as North American Pulsotype 1 (NAP1) emerged in the last 10 years, and is among the
most common C. difficile strains in healthcare settings (Lessa et al., 2015). The NAP1 stain
belongs to the ribotype 027 and toxin type III (Valiente et al., 2014). Along with increased
infections, relapse of infection is a major concern in CDI-recovered patients, and is observed in
20-30% of the reported cases (Barbut et al., 2000; Gerding et al., 2015). In addition, the
mortality associated with CDI in the US has increased from 5.7 per million to 23.7 per million
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from 1999 to 2004 (Redelings et al., 2007), and the incidence rate among hospitalized patients
doubled from 2001 to 2010 (Reveles et al., 2014). In 2011, 29,000 deaths were reported
nationwide from CDI (Lessa et al., 2015). Further, C. difficile has shown an increasing resistance
to antibiotics such as fluoroquinolones (Drudy et al., 2007), clindamycin, erythromycin,
metronidazole (Qiong & Haihui, 2015) and vancomycin (Kelly & LaMont, 2008). C. difficile
was recently classified as an “urgent threat” in terms of antibiotic resistance by the Centers for
Disease Control (CDC) (Evans & Safdar, 2015). Also, C. difficile has surpassed Staphylococcus
aureus with the highest percentage of hospital-acquired infections (Magill et al., 2014). The
increase in C. difficile infections in the community adds weight to the classification of C. difficile
as an urgent threat.
3. C. difficile pathogenesis
The most important predisposing factor for C. difficile infection is long-term antibiotic treatment.
Antibiotic therapy can disrupt gut microbial communities and allow colonization of opportunistic
pathogens such as C. difficile (Perez-Cobas et al., 2014). The main mode of transmission for CDI
is through the fecal-oral route (Hookman & Barkin, 2009). C. difficile spores are shed in the
feces and can remain viable in the environment and on hospital surfaces for up to 5 months.
(Siani et al., 2011). Spores are metabolically inactive structures that protect the genetic material,
and allow survival in the acidic stomach. Once spores reach the intestine, germination occurs and
does so more readily in the absence of normal intestinal flora, when individuals are undergoing
long-term antibiotic treatment. The presence of bile salts such as sodium taurocholate initiates
spore germination (Wheeldon et al., 2011). Following germination, vegetative cells grow and
multiply in the intestine and produce two potent toxins known as toxin A (TcdA) and toxin B
(TcdB).
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The C. difficile toxins are glucosyltransferase proteins, which have four functional domains
(Solomon, 2013). The catalytic domain inactivates Rho family GTPases by glycosylation, which
disrupts Rho GTPase function in maintaining the cytoskeleton integrity. Also, inactivation of
Rho GTPases disrupts F-actin regulation and inhibits proper functioning of epithelial cell tight
junctions (Rupnik et al., 2009). The cysteine protease domain is involved in autocatalytic
cleavage of the toxins through action with cellular inositol hexaphosphate kinase 1 (InsP6)
(Pruitt & Lacy, 2012). The next domain is responsible for the entry of the toxin into the cell
cytoplasm and the last domain allows receptor binding. Breakdown of tight junctions through the
action of the four domains causes fluid leakage and ultimately leads to diarrheal symptoms. The
specific effects of C. difficile toxin A are cell rounding and apoptosis in monocytes, which leads
to host immune response in secretion of proinflammatory cytokines (El Feghaly et al., 2015;
Monaghan, 2015; Solomon, 2013). Proinflammatory cytokines such as IL-8 attract neutrophils
which cause tissue damage upon the release of lytic enzymes. In more serious CDI cases,
additional cytokines involved in inflammatory response such as IL-12 and IL-1β are released,
which further damages epithelial tissue leading to a debris build-up known as a
pseudomembrane. Tise condition known as pseudomembranous colitis is characterized by raised
yellow plaques that persist during severe CDI. In the most severe cases, uncontrolled cytokine
release and diarrheal fluid loss can lead to shock and even death (Knight & Surawicz, 2013).
4. C. difficile infection
Annually in the United States a high number of C. difficile infections are reported, which
clinically manifest as asymptomatic, mild, moderate or severe. (Lessa et al., 2015; McDonald et
al., 2006). Asymptomatic CDI patients do not show clinical signs of infection, but can transmit
the disease through shedding of C. difficile spores in feces. Early studies showed high

10

asymptomatic carriage of C. difficile in neonatal infants (61%), but only a small number
developed CDI (Holst et al., 1981). Mild clinical symptoms of CDI are fever and abdominal
pain. As the infection progresses to moderate CDI, watery diarrhea with 10 to 15 bowel
movements per day is characteristic (Kelly & LaMont, 1998). In addition, patient blood samples
show leucocytosis with ≥15,000–20,000 white blood cells/mm3. As CDI becomes more severe,
abdominal pain increases due to ileo-colonic dilation and toxic megacolon can develop (Knight
& Surawicz, 2013). Also, toxins can be detected in the stools of patients, and blood tests detect
substantial leukocytosis (> 50,000/μL). Pseudomembranous colitis manifesting raised yellow
plaques from the release of inflammatory cells and necrotic epithelial debris can also develop.
An endoscopy is utilized clinically to visualize plaques. Severe cases of pseudomembranous
colitis can lead to sepsis, and if perforations develop at the mucosal level renal failure and death
can occur in the most severe cases (Sailhamer et al., 2009; Solomon, 2013).
Recurrent CDI is observed in 25-30% of individuals (Gerding et al., 2015). Subsequent
infections can occur from ingesting spores from surfaces or objects contaminated from spore
shedding by patients themselves or by other infected individuals or asymptomatic carriers.
Recurrent CDI infections can be severe and debilitating to patients.
5. Community-associated CDI
The Infectious Disease Society of America classifies community-associated C. difficile
infections (CA-CDI) as infections that occur in the community with no hospitalization within the
past 12 weeks or infections that occur within 48 h of hospital admission (Lessa, 2013; McDonald
et al., 2007). An overview study observing the risk of antibiotics in documented CA-CDI cases
observed that antibioitcs do increase the risk of CA-CDI; specifically clindamycin poses the
greatest risk, and fluoroquinolones and cephalosporins also increase the risk (Deshpande et al.,
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2013). A population study observed that CA-CDI affected younger individuals than hospitalacquired CDI, with a median age of 50 and 72, respectively (Khanna et al., 2012). In addition,
the study noted a high percentage of individuals requiring hospital treatment and incurring severe
and recurrent infections as a result of CA-CDI. The incidence of CA-CDI was investigated in
Monroe County, New York, and was found to be responsible for 18% of total CDI cases within
the county over a period of one year (Dumyati et al., 2012). Also, it was observed that CA-CDI
patients were younger and had fewer classical risk factors for CDI compared to patients in the
hospital-acquired CDI group. Investigators also observed that 21% of these patients reported
visiting a health-care facility with a family member within 12 weeks before CDI onset.
Therefore, minor exposure to health-care settings or contact with individuals under long-term
hospital care could increase the risk of CA-CDI.
6. C. difficile toxins
The gene encoding region for C. difficile toxins is located in the pathogenicity locus
(PaLoc), which varies by strain type (Neyrolles et al., 2011; Rupnik et al., 2005). The region
encodes for high molecular weight toxins, which are classified as exotoxins and are a part of the
large clostridial toxins family (Popoff & Bouvet, 2009). C. difficile toxins are the major
virulence factors involved in CDI disease manifestation and include an enterotoxin for toxin A
(TcdA) and a cytotoxin for toxin B (TcdB). TcdA is 308 kDa and TcdB is 270 kDa with
similarities in their amino acid sequence and function. Both toxins have an A subunit, which has
catalytic activity and a B subunit responsible for delivery of the A subunit to the host cell
(Davies et al., 2011). The A subunit is involved in inactivating Rho family GTPases by
glycosylation (Voth & Ballard, 2005). The B subunit is divided into three parts involved in
delivery of the A subunit; receptor-binding, pore-formation and autoproteolysis. Overall, toxins
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A and B act together through binding and internalization, pore formation, autoproteolysis and
finally inactivation of the Rho GTPases (Pruitt & Lacy, 2012). Experiments have shown that
TcdB has more prolific cell rounding capacity than TcdA, with a fold difference of 100-10,000.
Also, strains with TcdA−TcdB+ cause similar infection conditions to TcdA+TcdB+.
TcdA+TcdB− strains have been found to be nonpathogenic to hosts, indicating the importance of
toxin B (Sambol et al., 2000). In addition, binary toxins (CdtA and CdtB) are also produced by
many toxigenic C. difficile strains (Gerding et al., 2014). CdtA modifies actin by enzymatic
ADP-ribosyltransferase activity and CdtB binds to the host cell and aids in translocating CdtA.
The ADP-ribosyltransferase activity causes depolymerization of the actin cytoskeleton, which
leads to microtubule production on epithelial cells aiding in C. difficile attachment (Gerding et
al., 2014; Hemmasi et al., 2015). Experiments with strain TcdA−TcdB− but positive for binary
toxins still cause enterocyte damage, indicating the importance of binary toxins in CDI (Gerding
et al., 2014).

7. Regulation of C. difficile toxin production
Toxin A and toxin B are encoded by genes tcdA and tcdB, respectively, and are released
from vegetative C. difficile. The Paloc region contains the toxin genes and encodes for regulatory
proteins such as TcdR, TcdC and a holing-like protein, TcdE (Neyrolles et al., 2011). TcdR is an
alternative sigma factor that is a positive regulator of toxin production and induces transcription
of tcdA and tcdB (Bouvet & Popoff, 2008). The negative regulator of toxin production is TcdC,
which interferes with the ability of TcdR to recognize tcdA and tcdB promoters (Dupuy et al.,
2008). The tcdC gene is expressed during the exponential growth phase, earlier in the growing
cycle than tcdA, tcdB and tcdR genes. Morreover, it has been identified that high toxin producing
strains such as NAP1 have a mutation in tcdC, hence negative regulation of toxin production is
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disrupted (Carter et al., 2011). Lastly, TcdE is required for secretion of C. difficile toxins
(Govind et al., 2015).

The genes codY and ccpA are also involved in C. difficile toxin production, which are
located outside of the Paloc region (Dineen et al., 2010). CodY represses toxin production in C.
difficile, and is classified as a global regulator of virulence genes in many Gram-positive bacteria
(Lobel et al., 2012). During nutrient deprivation, branched-chain amino acids are present which
are shown to increase the binding affinity of codY to the tcdR promoter to supress toxin
production (Dineen et al., 2007). The ccpA gene codes for a protein functioning as a pleiotropic
regulator involved in carbon catabolite repression. CcpA identifies rapidly metabolizable
carbohydrate sources such as glucose and acts as the link between nitrogen and carbon pathways
(Antunes et al., 2011). Therefore, both ccpA and codY are involved in sensing nutrient
availability. In addition, the toxin genes (tcdA and tcdB) and the positive and negative regulators
(tcdR and tcdC) are regulated by CcpA. Interestingly, CcpA is also involved in repressing
sporulation through acting on Spo0A, which will be described further in subsequent sections
(Antunes et al., 2011; Pettit et al., 2014).

8. C. difficile and the microbiome

An important predisposing factor for C. difficile infection is the disruption of normal
garstrointestinal flora, collectively known as the microbiome. Disruption of the microbiome is
typically associated with long-term exposure to antibiotics (Britton & Young, 2014). It has been
demonstrated in studies with mouse models that antibiotics such as a single dose clindamycin
predispose to CDI susceptibility (Buffie et al., 2012). Exposure to antibiotics disrupts the
microbiome for prolonged periods, even after the treatment regimen is complete (Dethlefsen et
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al., 2008). The known classes of antibiotics which have been shown to predispose patients to
CDI are cephalosporins, clindamycin, fluoroquinolones and penicillins (McFarland, 2008).
Fidaxomicin is a narrow spectrum antibiotic that was recently approved for CDI treatment ,and
has shown less disruption of microflora. In addition, fidaxomicin treatment is associated with a
reduced rate of CDI recurrence compared to treatment with vancomycin (Louie et al., 2011).
This highlights the importance of the microbiome in CDI prevention and protection against
reccurent infections. Fecal transplant from healthy individuals for re-establishing a healthy
microbiome in CDI patients will be discussed in the “Treatments for CDI in humans” section of
this review.

It has been observed that the composition of the gut microbiome becomes less diverse in
elderly individuals. The protective classes of bacteria such as Bifidobacterium and Firmicutes
decrease significantly in the elderly and the pathogenic bacterial class known as Proteobacteria
increase (Biagi et al., 2010; Claesson et al., 2011). These alterations in the microbiome of the
elderly can lead to gut dysbiosis and plays a role in predisposition to CDI (Mariat et al., 2009).

9. Environmental isolation of C. difficile

A pivotal study which isolated C. difficile from the environment was conducted in Wales,
from a total of 2580 environmental samples, and identified positive isolates from soil, river
water, sea water and animal feces (al Saif & Brazier, 1996). An environmental sampling in
Zimbabwe found positive hyper-virulent C. difficile isolates in soil (37%), water (6%) and
animal fecal samples (4.3%) (Simango, 2006). Environmental C. difficile isolates were obtained
in Slovenia from puddle water (14.4% of n=104) and soil (36.7% of n=79), with diverse
ribotypes suggesting high genetic diversity of C. difficile in the environment (Janezic et al.,
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2016). C. difficile is also present in rivers and was found to be present in 68% of rivers in a
recent study conducted in Slovenian rivers (Zidaric et al., 2010). A large study of 786 C. difficile
isolates obtained from humans, animals and the environment were analyzed by polymerase chain
reaction (PCR) to determine the ribotype and toxin grouping for each sample (Janezic et al.,
2012). It was determined that samples in the environment contained the highest percentage of
non-toxigenic strains (30.8%), while samples from humans and animals were more similar and
contained a lower percentage of non-toxigenic strains (6.5% and 7.7%, respectively). Overall the
study found that many C. difficile strains from humans are present in both animals and the
environment. Therefore, the ubiquitous presence of C. difficile in the environment could be a
source for community-associated outbreaks.

Sludge and wastewater samples in Switzerland and Slovenia were tested for presence of
C. difficile, and 13 ribotypes with 85% toxigenic and 32 ribotypes with 3.3% toxigenic were
identified, respectively, in each study (Romano et al., 2012; Steyer et al., 2015). Ribotypes 010
and 014 were most prevalent in Slovenia and 078 in Switzerland, which are similar to ribotypes
isolated from humans, animals and water sources. A similar study in Canada identified a high
prevalence of C. difficile in raw sludge (92%) and river sediments (60%), where processed waste
water is released (Xu et al., 2014).

10. C. difficile in animals

Healthy domestic animals have been found to shed C. difficile in their fecal material. Positive C.
difficile isolates are shed more readily in young animals such as calves and piglets but adult
animals on farms and prior to slaughter also test positive for C. difficile (Keel et al., 2007;
Rodriguez et al., 2012; Silva et al., 2015). Sampling data from 1500 neonatal piglets over 5 years
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indicated that 67% of litters and 35% of individual pigs were positive for toxigenic C. difficile
(Songer & Anderson, 2006). Another study in the US isolated C. difficile ribotype 078 from 83%
of neonatal pig samples and 94% of calf samples (Keel et al., 2007). In the Netherlands, identical
078 C. difficile strains were isolated from pigs and humans with similar susceptibility profiles to
antimicrobials (Debast et al., 2009). A study in Brazil identified positive isolates in dogs, foals,
piglets and calves, with strains similar to human isolates, illustrating the potential for zoonotic
transmission of C. difficile (Silva et al., 2015). C. difficile was detected in pets such as dogs and
cats at high prevalence rates with confirmed shedding of spores in feces (Álvarez‐ Pérez et al.,
2015; Koene et al., 2012; Riley et al., 1991). In addition, a recent study in 2013 confirmed that
carcass contamination of pigs and cattle occurs in slaughter plants as observed in 7% of
carcasses (Rodriguez et al., 2013). A US study in 875 food animals identified a prevalence rate
of < 0.6% in poultry, cattle and swine (Rodriguez-Palacios et al., 2014b). Overall the prevalence
rate of C. difficile in food animals and foods has been varied over the past decade (Costa et al.,
2012; Lund & Peck, 2015), but there is a potential for C. difficile as a foodborne pathogen.
C. difficile has also been detected in wild animals such as raccoons, which could play a
role in transmitting the pathogen. A study isolated C. difficile strains from 12% of raccoon feces
tested, and five of the 19 strains identified were human strains. Raccoons were tested on multiple
occasions and were observed to not be positive for C. difficile more than once, suggesting that
raccoons could transmit the pathogen to sites such as farms (Bondo et al., 2015). C. difficile has
been detected in other wild animals such as feral pigs, elk, and in an ocelot that was treated with
antibiotics (Arroyo et al., 2005; Silva et al., 2013; Thakur et al., 2011). Also, migrating European
barn swallows captured at different locations for fecal sample collection were positive for C.
difficile (Bandelj et al., 2014). Many studies isolated ribotype 078 from wild animals, which
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suggests a potential reason for the increased incidence of 078 in community-associated CDI.
However, to date, transmission of C. difficile between species has not been confirmed, but could
occur from contact with feces by humans or other animals though the fecal-oral route.
11. Animal-derived foods as a source of C. difficile
The rise in community-associated C. difficile infections has suggested food as a
possible source of C. difficile infection. In addition, genotypically similar or identical strains of
C. difficile strains implicated in human infections have been identified in foods and food animals.
An initial study of C. difficile contamination in retail meat showed a 21% prevalence rate from
53 ground beef samples, and a 14% prevalence rate from 7 ground veal samples obtained from
stores in Canada (Rodriguez-Palacios et al., 2007). A follow-up study with a larger number of
samples indicated lower prevalence rates of 6.7% out of 149 ground beef samples and 4.6% out
of 65 veal chop samples (Rodriguez-Palacios et al., 2009). Overall, the prevalence of C. difficile
in ground beef in the US has ranged between 0 to 44% (Houser et al., 2011; Songer et al., 2009).
On the other hand, the prevalence rate of C. difficile in chicken and poultry products has ranged
from 0 to 12.5% (Harvey et al., 2011a; Weese et al., 2010).
There are limited studies on the prevalence of C. difficile in pre-cooked ready-to-eat
meats (RTE). One study in Texas focused on the prevalence of C. difficile in pork used to make
ready-to-eat sausage, and identified the bacterium in 9.5% of 234 samples tested (Harvey et al.,
2011b). A study of both uncooked and ready-to-eat retail meats, found a higher percentage of
positive C. difficile isolates in RTE meats with isolates found in 62.5% of pork braunschweiger
compared to 50% in ground beef (Songer et al., 2009). A more recent study identified toxigenic
C. difficile isolates in 3 of 15 ready-to-eat pork products, braised skin and braised colon products
(Wu et al., 2017).
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12. C. difficile in vegetables
The prevalence of C. difficile in fresh produce has been investigated in fewer studies
compared to that in meat. The incidence of C. difficile in vegetables would pose a greater risk
since many are not cooked prior to consumption. In France, 60 ready-to-eat lettuce (REL)
samples and 44 vegetables, including broccoli, carrots and beets were tested for C. difficile. The
overall prevalence rate was 2.9%, with two samples of REL and one pea sprout sample testing
positive (Eckert et al., 2013). A study in Scotland found C. difficile in 7.5% of 40 REL samples,
identifying ribotypes 001 and 017 (Bakri et al., 2009). The isolated strains were resistant to
moxifloxacin and clindamycin. The presence of C. difficile in vegetables could be from farm
workers or environmental sources such as contaminated water, soil or fertilizer. A study
conducted in ready-made salads for foodservice in Iran isolated C. difficile in 5.66% (6/106) of
samples tested (Yamoudy et al., 2015) The only prevalence study in fresh produce in the US was
conducted in Ohio, and 2.4% of 125 vegetable samples tested positive for C. difficile. One of the
C. difficile strains was resistant to moxifloxacin and clindamycin. This US study found toxigenic
C. difficile isolates in ready-to-eat vegetables such as pepper and lettuce, but did not investigate
the prevalence in REL (Rodriguez-Palacios et al., 2014a). The majority of prevalence studies in
vegetables did not quantify the level of C. difficile contamination, but many studies assumed that
strains were isolated from spores instead of vegetative cells. The infectious dose of C. difficile is
not confirmed, but a low level of C. difficile spore contamination could likely cause infection,
especially in susceptible individuals (Lund & Peck, 2015).
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13. Isolation of C. difficile from hospital environment
C. difficile spores are shed in the feces of infected individuals, which serves as a
source of new and recurrent infections. Studies have indicated that C. difficile spores can survive
in the hospital environment on surfaces and inanimate objects for up to 5 months (Hasan et al.,
2011; Kim et al., 1981; Owens, 2006). Also, healthcare workers contribute to C. difficile
transmission by touching contaminated surfaces or individuals, and directly spreading the
pathogen (Boyce, 2007; Guerrero et al., 2012). C. difficile spores have been commonly isolated
from hospital rooms on floors, bedpans, bed rails and furniture (Kim et al., 1981; Weber et al.,
2013). C. difficile contamination in the rooms of CDI patients ranged from 2.9-75% (Weber et
al., 2010). In addition, spores have been isolated from equipment shared between patients such as
blood pressure cuffs and stethoscopes (Fekety et al., 1981; Gerding et al., 2008). There is a high
transfer rate of C. difficile spores from healthcare workers’ gloved hands after contact with
patients, inanimate objects, and reverse transfer is also observed (Guerrero et al., 2012). C.
difficile spores are also present in the air space surrounding patients (Roberts et al., 2008). Sharps
containers are re-used in 50% of healthcare facilities and were investigated as a potential source
of C. difficile. The data obtained from 604 hospitals found that hospitals which used single-use
containers had significantly lower rates of C. difficile infections in their facilities (PogorzelskaMaziarz, 2015). Therefore, it is accepted that there is a high rate of contamination of the hospital
environment with C. difficile spores, which plays a critical role in CDI transmission.
14. Hospital disinfectants against C. difficile
C. difficile spores can survive on hospital surfaces for several months (Barbut et al.,
2009; Fawley et al., 2007). Patients infected with C. difficile shed between 104 and 107 spores per
gram of feces (Mulligan et al., 1984). Transmission and relapse of infection occurs from
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ingestion of C. difficile spores from the environment. Commonly used hospital cleaning agents,
such as quaternary ammonium–based and other surfactant-based detergents, do not kill C.
difficile spores, and may potentially increase the sporulation capacity of C. difficile (Gerding et
al., 2008). Currently, the only disinfectant recommended for use during C. difficile outbreaks is
1:10 sodium hypochlorite solution with 10 min of contact time (Cohen et al., 2010; Edwards et
al., 2016; Fawley et al., 2007). Sodium hypochlorite has been shown to decrease the incidence of
C. difficile infection in cross-over studies in hospitals (Wilcox et al., 2003). However, high
concentrations of sodium hypochlorite are associated with skin irritation, respiratory distress in
healthcare workers and patients, and corrosion of hospital equipment and surfaces (Keward,
2013). In addition, the 10% sodium hypochlorite solution must be prepared daily in order to
achieve an effective concentration, which requires additional compliance measures for hospital
staff (Dubberke et al., 2008).
Alternative disinfection methods using automated technology have recently emerged
such as hydrogen peroxide vapor and ultraviolet-C emission (Anderson et al., 2013; Shapey et
al., 2008). Specialized equipment is required for these disinfection techniques and hospital rooms
need to be vacated during the procedure, making these processes lengthy and not-cost effective.
In addition, the automated disinfection system with hydrogen peroxide showed statistically
similar effectiveness to disinfection with sodium hypochlorite, indicating the need for continued
research in disinfection procedures (Mosci et al., 2017). Currently, disinfection with 10% sodium
hypochlorite disinfection is deemed as most effective against C. difficile spores, but is associated
with health risks, equipment damage and risk of using ineffective concentrations.
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15. C. difficile spores
C. difficile spores are dormant structures which perpetuate survival in the environment
and allow transmission from host to host. The metabolic dormancy of C. difficile spores allows
resistance to oxygen, disinfectants, antibiotics and common heat treatments (Ali et al., 2011;
Baines et al., 2009). This resistance is due to low water content of spores (25-60% of wet
weight), high amount of dipicolonic acid and saturation of DNA with protective α/β soluble

proteins (Paredes-Sabja et al., 2014). The saturation os The spore-core containing DNA is
protected by an impermeable inner membrane comprised of phospholipids, which prevent the
passage of water. The next layer is the germ cell wall, which becomes the cell wall in the
vegetative state. The cortex layer is made of peptidoglycan with every second muramic acid
residue converted to muramic-δ-lactam (MAL) to reduce crosslinking. The MAL residues allow
lytic enzymes to hydrolyze the spore cortex during germination due to less crosslinking
compared to the cell wall layer. The proteinaceous coat helps with spore resistance to stresses
(Permpoonpattana et al., 2011). Finally, the exosporium layer is a loose-fitting layer with hairlike projections similar to B. anthracis (Henriques & Moran, 2007). This layer plays a role in
hydrophobicity, which affects the ability of spores to attach to surfaces (Joshi et al., 2012). Five
proteins that are located in the outer layers of C. difficile spores are CotA, CotB, CotCB, CotD,
and CotE, but only CotA is needed for the assembly of the exosporium (Permpoonpattana et al.,
2011). The proteins CotD and CotE have demonstrated antioxidant activity to reduce H2O2
toxicity through conversion to water and oxygen (Permpoonpattana et al., 2011). In addition, a
newly identified protein in the exosporium known as Clostridium difficile exosporium cysteinerich protein (CdeC) was found to be expressed during sporulation, and is required for the correct
assembly and development of the spore coat and exosporium. By using a spore ΔcdeC knockout
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mutant, researchers found that mutants lacked an exosporium layer were more sensitive to
ethanol and heat treatment, indicating that CdeC is necessary for exosporium development and
resistance characteristics (Barra-Carrasco et al., 2013). Also, the ΔcdeC mutants attached more
readily to intestinal epithelial cells suggesting the protein’s function in wild type spores in
decreasing adherence, potentially so they can be more readily excreted in the feces.
16. Sporulation of C. difficile

Sporulation of C. difficile typically occurs during the stationary phase or death phase after
72 h of anaerobic incubation. Sporulation of C. difficile is a virulence factor which perpetuates
the bacterium by the production of survival structures known as spores that can persist in
infected hosts and in the environment. Being a strict anaerobe, spore formation also allows C.
difficile to be protected from the toxic effects of oxygen (Sorg & Sonenshein, 2008). Sporulation
is initiated by various environmental stresses such as nutrient deprivation and other stress factors
which are not fully understood (Higgins & Dworkin, 2012). This process occurs at the time of
egestion in the host, followed by shedding of spores in the feces.

The genes involved early in the sporulation process of C. difficile include spoOA, sigH
and codY. The gene sigH is a transition phase sigma factor involved in the transcription of
spoOA to initiate sporulation (Saujet et al., 2014). The gene spoOA is identified as the master
regulator of sporulation (Babakhani et al., 2012). In a recent study, it was illustrated that a
Δspo0A C. difficile strain was unable to survive and perpetuate in a mouse model with the
absence spore formation (Deakin et al., 2012). There are five orphan histidine kinases (CD1352,
CD1492, CD1579, CD1949, and CD2492), which are required to phosphorylate the master
regulator of sporulation, Spo0A, for sporulation to proceed. CD1492, CD1579, and CD2492 are
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located in the codY gene, and are classified as SpoOA-specific (Underwood et al., 2009). In
particular, the histidine kinase CD 1579 has been shown to directly transfer the phosphoryl group
to Spo0A for initiation, but autophosphorylation has not been proven with the other 4 kinases.
However, CD1492 and CD2492 have also been shown to have conserved genome regions for
autophosphorylation.

The sporulation process in Bacillus subtilis and C. difficile are similar, but vary at the
level of regulation by the RNA polymerase sigma factors (σF, σE, σG, and σK). In C. difficile
sporulation, there are more deviations between gene expression and morphogenesis of the
forespore being engulfed by the mother cell. The two species share compartment-specific
activation with σF and σG involved in forespore activity, and σE and σK activity with the mother
cell (Fimlaid et al., 2013). Moreover, σF is necessary for post-translational activation of σG, but
is not necessary for proteolytic activation of σE. A difference in C. difficile is the lack of
necessity for σF to activate σE, but the forespore protein SpoIIR is required for σE activation
(Saujet et al., 2014). The σE expression has been shown to be dependent on SpoOA, the master
regulator. Also, σE plays a role in the transcription of genes such as spoIIID, which encodes for a
regulator in the mother cell. The factors σE, σG and spoIIID are needed for σK production and
activation, but σK does not require proteolytic activation (Paredes-Sabja et al., 2014).
Signaling regulation of sporulation leads to spore cell formation with asymmetric division into a
small forespore and a larger mother cell. The forespore is the portion that will become the spore.
The mother cell engulfs the forespore and initiates the cortex, coat and exosporium layers to
form. In C. difficile, SpoIVA is required for localizing the spore coat around the forespore and
acts directly with a newly characterized protein, CD3567 (Putnam et al., 2013). Therefore, this
interaction is required for the beginning stages of spore layer assembly. In summary, the known
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factors of the spores include SpoIVA and CD3567, which are proteins involved in localization at
the basement layer. The factors involved in inner coat, outer coat and crust formation are not yet
known for C. difficile. CdeC is the protein required for exosporium development and assembly.
Lastly, the BclA1 glycoproteins spanning out through the exosporium layer important in C.
difficile spores. Research suggests that the lower degree of regulation of sporulation and check
points in C. difficile may be an adaptation for surviving in the gut of infected hosts (Saujet et al.,
2014).
17. Germination of C. difficile
When initiation of spore germination occurs, a phase bright spore changes to a phase
dark spore as germination receptors are activated by specific bile salts (Sorg & Sonenshein,
2008; Wax et al., 1967). Studies have shown that taurocholate, a derivative of cholate, acts as a
germinant and L-glycine acts as a co-germinant (Sorg & Sonenshein, 2008). A 1 min exposure
time to 0.1% taurocholate showed improved spore recovery compared to media without
taurocholate indicating its activity as a germinant (Sorg & Sonenshein, 2008). The interaction
between the germinant and co-germinant causes enzymatic reactions that ultimately release Ca2+
and dipicolinic acid from the spore core (Setlow, 2003). The spore becomes rehydrated and the
cortex degrades, ultimately leading to vegetative growth. The CotE spore coat protein described
in the spore section also has chitinase activity observed at the time of germination, which
involves the breakdown of components into nutrients. The presence of germinants allows more
prolific germination, but some C. difficile strains have been shown to germinate in media without
taurocholate, indicating that the process is highly complex. C. difficile has different germination
receptors than B. subtilis, and one of these has recently been identified as CspC. This serine
protease acts as a bile salt germination receptor and induces the release of Ca-dipicolonic acid
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upon bile salt interaction. Following bile salt interaction, CspC activates CspB, which then
activates SleC which presumably leads to cortex hydration. Next, ions and Ca-dipicolonic acid
are thought to be released, which allows spore core hydration ending in spore outgrowth to a
vegetative cell (Paredes-Sabja et al., 2014).
18. Treatments for CDI in humans
18.1 Antibiotics
Medical management of C. difficile infection is a challenge in hospital settings
since the treatment of C. difficile is frequently complicated by relapse of infection.
Metronidazole administered orally is prescribed for treating mild to moderate CDI as 500 mg 3
times a day for a 10 day regimen. For more severe CDI, and for pregnant or lactating women
with CDI, the suggested antibiotic is oral vancomycin at 125 mg 4 times a day for a 10 day
regimen. A higher dose of oral vancomycin is prescribed for most severe CDI cases at 250-500
mg 4 times a day for a 10 day regimen. Also, vancomycin can be administered rectally if
conditions exist, where oral administration would not allow sufficient delivery (Knight &
Surawicz, 2013). Treatment for initial CDI with 10 to 14 days of metronidazole or vancomycin
have cleared infections in 50% of patients (Longo et al., 2015).
In case of recurrent CDI, the same antibiotic treatment prescribed could be represcribed. For a second recurrence, oral vancomycin should be prescribed with an extended
“pulsed” course involving the use of intermittent high and low doses every 2 to 3 days. Pulsed
dosing has shown effectiveness in clinical trials involving patients with recurrent CDI and
showed a lower recurrence rate of 31% for pulsed dose compared to 40-50% for conventional
dosing (McFarland et al., 2002). A recently identified antibiotic, fidaxomicin, was shown
effective against CDI and prevented recurrent infections more effictively than vancomycin
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(Housman et al., 2015; Zhanel et al., 2015). The antimicrobial activity of fidaxomicin is through
inhibition of RNA polymerase to prevent transcription. The antibiotic also produces a
bactericidal compound OP-1118, which acts against C. difficile for up to 10 h after antibiotic
administration. Clinical trials showed that 200 mg of fidaxomicin two times daily for 10 days
was as effective as 125 mg of vancomycin four times daily for 10 days. Also, this trial indicated
the ability of fidaxomicin to prevent recurrent CDI more effectively than vancomycin (Zhanel et
al., 2015).
18.2 Probiotics
C. difficile is the primary cause of antibiotic-associated diarrhea (Johanesen et
al., 2015). Therefore, a preventative treatment which can be administered before antibiotics or
concurrently with antibiotics could reduce the frequency of recurrent CDI. Probiotics are defined
as “live microorganisms that when administered in adequate amounts confer a health benefit on
the host” (Sanders, 2008). The protective effect of probiotics is through anti-inflammatory
signalling in the gut. Clinical trials with live bacterial species (Saccharomyces boulardii,
Lactobacillus acidophilus and Lactobacillus casei) have been shown effective in preventing
recurrent CDI (Johnson et al., 2012). Probiotics are primarily prescribed along with antibiotic
treatments in order to maintain desirable microfloral populations classically eliminated during
antibiotic regimens. Clinical trials with probiotics have been more effective as a secondary
prevention against recurrent CDI as compared to a primary treatment. A clinical trial including
children taking antibiotics for ear or respiratory infections were randomly assigned S. boulardii
treatment or placebo. The results showed significantly less incidence of antibiotic-associated
diarrhea in the probiotic group (3.4%) compared to the placebo group (17.3%) (Kotowska et al.,
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2005). However, this lower incidence of antibiotic-associated diarrhea cannot be linked to
preventing C. difficile infection.
A meta-analysis of numerous controlled trials of primary CDI prevention in patients
taking antibiotics showed a significant reduction in CDI (Crow et al., 2015). A study focusing on
CDI prevention included patients with CDI assigned to one of two groups with vancomycin plus
S. boulardii or vancomycin plus a placebo. The administration of probiotic showed a significant
decrease in CDI recurrence at a rate of 16.7% for the S. boulardii group and 50% for the placebo
group (Surawicz et al., 2000). Another experiment included patients taking antibiotics assigned
to a group with a probiotic mixture drink (Lactobacillus casei, Lactobacillus bulgaricus and
Streptococcus thermophilus) or a placebo drink. There was no incidence of CDI in the group
administered the probiotic compared to a 17% incidence of CDI in the placebo group (Hickson et
al., 2007). A recent study conducted in high risk patients undergoing antibiotic therapy in the
nephrology and transplantation wards of a hospital showed that daily administration of
Lactobacillus plantarum 299v prevented CDI compared to the observation period when
probiotics were not administered (Kujawa-Szewieczek et al., 2015). A recent meta-analysis of
controlled trials investigating the effectiveness of probiotics as a secondary treatment for CDI
found the highest significance for S. boulardii (Crow et al., 2015). However, the overall data are
still limited in CDI patients and additional experiments are needed to evaluate the safety of
probiotics for immunocompromised patients.
18.3 Immunization
Protection from mortality from CDI has been demonstrated in animals administered
toxoids TcdA and TcdB (Siddiqui et al., 2012). The toxoids have been shown to confer an
immune challenge, which allows natural production of IgG antitoxins. Hamsters administered

28

with the toxoid vaccine showed 100% protection from mortality when challenged with a lethal
A-/B+ C. difficile strain (Siddiqui et al., 2012). The safety of toxoid A and B parenteral vaccine
was tested in healthy adults and found to be safe, producing an antibody response in over 90% of
patients tested (Kotloff et al., 2001). An international clinical trial with Health Authorities from
numerous countries (ClinicalTrials.gov number NCT01887912) is currently investigating a C.
difficile toxoid vaccine (Cdiffense vaccine) in subjects characterized as at risk for CDI (Longo et
al., 2015). Injections containing the toxoids or a placebo will be administered in 3 doses on days
0, 7 and 30, and the safety and immunogenicity will be evaluated after each injection. A total of
15,000 participants will be included in the study and follow up assessments will be conducted
three years after vaccination. The study is currently ongoing until 2017, and the results are
expected to help determine if the vaccine has long term immunogenic effects, besides studying
the potential for risk reduction of CDI. It is predicted that vaccination will not prevent C. difficile
colonization, but it may lessen the severity of infection (Longo et al., 2015).
18.4 Fecal transplantation
The microbial population in the colon plays an important role in preventing
colonization by pathogenic bacteria, including C. difficile. Antibiotic treatments disrupt the
diversity of the microbiota and long-term administration predisposes patients to CDI. In addition,
it takes at least 12 weeks for the colonic microbiota to re-establish following an antibiotic
regimen (Dethlefsen et al., 2008; Jernberg et al., 2007). During this recovery period, recurrent C.
difficile infections can occur. Fecal transplantation is a treatment to prevent relapse of CDI,
where fecal material from healthy donors is used to replace important microflora, particularly in
the Bacteroidetes and Firmicutes phyla. The procedure was first used in 1958, but has recently
been deemed as a safe and viable treatment option for recurrent CDI (EISEMAN et al., 1958;
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Kassam et al., 2013). Patients with recurrent CDI that receive oral or rectal fecal transplantation
treatments and stop antibiotic therapy show 90% success in treatment (Kassam et al., 2013). A
randomized trial using vancomycin followed by fecal transplantation or vancomycin alone
showed greater efficacy against CDI for the combination treatment (van Nood et al., 2013). A
randomized double-blind clinical trail involving 219 patients with recurrent CDI used treatment
of frozen or fresh fecal transplant. Both fecal transplantation treatment types showed efficacy in
reducing reccurence of CDI (Lee et al., 2016). Studies investigating the efficacy of fecal
transplantation in treating primary CDI are currently underway (Schenck et al., 2015).
18.5 Bacteriophage treatment
The use of bacteriophages has recently been approved for use in foods to prevent
foodborne disease outbreaks (Hagens & Loessner, 2010). This highlights the safety of
bacteriophages as antimicrobials. Bacteriophages can be used as an alternative treatment to
target C. difficile in the gastrointestinal tract and prevent colonization. However, it has been
difficult to isolate bacteriophages that are strictly virulent against C. difficile (Hargreaves &
Clokie, 2015). Bacteriophages act by attaching to receptors on C. difficile, inserting their DNA,
which allows phage replication and eventually causes lysis of C. difficile cells. A study to
identify a phage effective against C. difficile was conducted and a specific four-phage
combination (phiCDHM1-phiCDHM2-phiCDHM5-phiCDHM6) was identified as most effective
in lysing C. difficile and preventing resistant clones. The bacteriophage combination was
delivered to hamsters and C. difficile colonization was reduced significantly (Nale et al., 2015).
Therefore, this treatment method could be effective in treating CDI in humans. Novel phage taillike particles (PTLP) have been identified, which are similar to bacteriophages, but do not
require DNA transmission into the target cell. In an experiment, PTLP were isolated from CDI
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patient tissue samples and were found to act specifically against C. difficile cells (Sangster et al.,
2015). However, additional studies are necessary to confirm the efficacy of this treatment.
18.6 Nontoxigenic strains for controlling recurrent CDI
The non-toxigenic C. difficile strain VP20621 was evaluated for safety in healthy
individuals between 18-45 years of age. Test subjects received vancomycin and then oral
suspensions of the nontoxigenic strain spores or a placebo. The VP20621 strain was found to be
safe, able to colonize the gastrointestinal tract, and recovered in the stools of all patients
administered the treatment dose (Villano et al., 2012). A follow-up study was completed to
determine the efficacy of the nontoxigenic C. difficile strain M3 (VP20621; NTCD-M3) in
preventing recurrent CDI. A double-blind study was conducted in individuals with CDI that had
been treated with metrondizole, vancomycin or both antibiotics. The patients were administered
a placebo treatment or a treatment of varying nontoxigenic strain spore counts daily for 7 days.
The nontoxigenic M3 C. difficile strain was found to be safe, had the ability to colonize the
gastrointestinal tract of patients and significantly reduced the rate of recurrent CDI (Gerding et
al., 2015).
18.7 Alternative treatment
Aspirin (acetylsalicylic acid ) is a well-known non-steroidal anti-inflammatory drug
(NSAID). Aspirin is the most widely used drug in the field of medicine (Soni, 2005). The US
Preventative Services Task Force recommends daily low dose aspirin (≤ 30mg) for the
prevention of cardiovascular disease as a preventative for recurrent cardiovascular events
(Ittaman et al., 2014; US Preventive Services Task Force, 2009). Low dose aspirin has been
shown to reduce the aggregation of platelets which prevents blood vessel obstruction and reduces
the risk of heart attack and stroke (Dippel et al., 2004). Therefore, it is readily prescribed to
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patients as a daily medication. Aspirin was recently identified as a factor that reduced mortality
from CDI in a clinical observational study of adults diagnosed with CDI (Saliba et al., 2014).
However, the mechanism of action involved in reduced CDI mortality by aspirin is unknown, but
could potentially act through reduced toxin production, sporulation or spore outgrowth of C.
difficile.
In summary, the isolation of genetically similar and identical strains of C. difficile in the
environment, food animals and humans indicates the potential for food to be a source of CDI
(Debast et al., 2009; Silva et al., 2015). C. difficile has been detected in retail meats, especially
ground beef, but its survival during storage, cooking and acidic conditions has not been
previously investigated. Moreover, US prevalence studies of C. difficile in vegetables, especially
in ready-to-eat lettuce, are limited. Further, C. difficile is widely transmitted in hospital settings
and relapse frequently occurs from re-ingestion of spores. C. difficile spores can survive in the
abiotic environment such as on hospital surfaces and equipment for extended periods of time.
Therefore, effective disinfection of hospital equipment and surfaces could control transmission
of CDI.
This dissertation hypothesized that C. difficile is potentially present in ready-to-eat
lettuce, where it can survive under modified atmosphere packaging conditions. Also, C. difficile
spores in ground beef will survive the effect of chilling, freezing and cooking, and the effect of
acidity in fermented pork summer sausage. In addition, it was hypothesized that octenidine
hydrochloride will be effective in reducing C. difficile spores on stainless steel surface, and
acetylsalicylic acid (aspirin) will decrease C. difficile sporulation and germination.
The specific objectives of this dissertation are to:
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1. Determine the prevalence of C. difficile in ready-to-eat lettuce (REL) in Connecticut, and
study the effect of modified atmosphere packaging (MAP) on the viability of C. difficile spores
in REL.
2. Determine the effect of chilling, freezing and cooking on the viability of C. difficile spores in
ground beef.
3. Study the effect of acidity and cooking on the viability of C. difficile spores in fermented pork
summer sausage.
4. Determine the efficacy of octenidine hydrochloride (OH) in reducing C. difficile spores on
stainless steel surfaces.
5. Investigate the effect of aspirin on C. difficile sporulation and spore germination in vitro.
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Chapter III
Prevalence of C. difficile in ready-to-eat lettuce (REL) in Connecticut, and the effect of
modified atmosphere packaging (MAP) on the viability of Clostridium difficile spores on
REL
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Abstract
Clostridium difficile is a nosocomial pathogen with significant public health implications
in humans. However, recent trends have shown increased C. difficile infections in communities
outside of hospital environments. Additionally, C. difficile has been detected in water, soil, food
animals, animal feces and foods such as meat and vegetables. Fresh produce is grown in contact
with soil and water and may not be cooked prior to consumption. Therefore, there is an increased
risk of contamination of fresh produce with C. difficile. This study was conducted to investigate
the prevalence of C. difficile in ready-to-eat lettuce (REL) and to determine the survival of C.
difficile spores on REL under modified atmosphere packaging (MAP) conditions.
One hundred and fifty samples of REL were collected from geographically distant, retail
stores in Connecticut and tested for the presence of C. difficile. Lettuce samples (25 g) were mixed
with C. difficile moxalactum norfloxacin broth (25 ml) with 0.1% (w/v) sodium taurocholate
(CDMNT), and 1 ml aliquots were alcohol-shocked and pour-plated with CDMNT agar followed
by 48 h of anaerobic incubation at 37oC for enrichment. Positive isolates were confirmed by Gram
staining, L-proline aminopeptidase test, PCR targeting C. difficile housekeeping tpi gene, and toxin
A and B genes. Further, the isolates were characterized by ribotyping and antibiotic resistance. A
follow-up study was conducted to investigate the effect of MAP conditions (2% O2, 5% CO2 and
93% N2) on the survival of C. difficile spores on REL under refrigeration. REL samples were
inoculated with hyper-virulent C. difficile spores at 2.0 log CFU/g and 4.0 log CFU/g, and
refrigerated under MAP conditions for 10 days. Enumeration of C. difficile on selective CDMNT
agar was done on days 0, 1, 3, 5, 7 and 10.
Thirty-five REL samples out of 150 (23%) tested positive initially for C. difficile, and all
isolates were found to contain the genes encoding for toxin A and B. However, none of the positive
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REL yielded any C. difficile by direct plating. In addition, all isolates were found to belong to the
ribotype 027. Twenty of the isolates were tested for sensitivity to ten clinical antimicrobials and
were found to be multi-drug resistant. Results showed that C. difficile spores remained viable on
REL under MAP conditions throughout 10 days of storage. Although the results suggest the
presence of C. difficile on REL and the viability of C. difficile spores under MAP storage
conditions, the potential role of REL in community-acquired C. difficile infection in humans
requires additional investigation.
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1. Introduction
Clostridium difficile is a gram-positive, spore-forming, anaerobic, nosocomial pathogen
affecting hospitalized patients taking long-term antibiotics. However, a new trend has shown an
increase in community-associated C. difficile infections (CA-CDI), especially in individuals who
are not taking long term antibiotics and are not residing in hospital settings (Hensgens et al., 2012;
Lessa, 2013). The source of infection of CA-CDI is currently not known, but food could be a
potential source of the pathogen. An additional trend in the epidemiology of C. difficile is the
emergence of a new hypervirulent strain belonging to PCR ribotype 027, which is reported in
major outbreaks in Europe, Canada, Australia, and the United States (Cassir et al., 2016; He et al.,
2013; Kuijper et al., 2006; Miller et al., 2010).
C. difficile is present in the environment and has been detected in water from lakes, rivers
and wastewater effluent, in addition to various soil types in both farms and densely populated areas
(al Saif & Brazier, 1996; Janezic et al., 2016; Steyer et al., 2015; Zidaric et al., 2010). C. difficile
has also been isolated from the feces of livestock such as cattle and pigs, and from foods such as
meat, shellfish and vegetables (Costa et al., 2012; Eckert et al., 2013; Janezic et al., 2012; Pasquale
et al., 2011; Rodriguez-Palacios et al., 2007). C. difficile strains isolated from the environment and
foods have been found genotypically similar or identical to strains implicated in CA-CDI cases
(Debast et al., 2009; Silva et al., 2015). Therefore, food is increasingly being investigated as a
potential source of CA-CDI, although no foodborne outbreaks have been reported to date (Gould
& Limbago, 2010). Studies in Scotland, France, Canada, Iran and in the US (Ohio) have detected
C. difficile in vegetables and ready-made-salads at rates of 7.5% (3/40), 3.33% (2/60), 4.5%
(5/111), 5.66% (6/106) and 2.4% (3/125) respectively (Bakri et al., 2009; Eckert et al., 2013;
Rodriguez-Palacios et al., 2014; Yamoudy et al., 2015). Further, the strains isolated from these
studies above were genotypically similar to strains implicated in human infections, such as
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ribotypes 001, 014, 027 and 078 (Eckert et al., 2013; Metcalf et al., 2010), thereby strengthening
the potential role of fresh produce as a source of CA-CDI.
Lettuce is the dominant salad green consumed in the U.S. Head lettuce can be either field
packed for bulk sale or transported to commercial facilities for further processing to ready-to-eat
lettuce (REL) (AMRC, 2014). Ready-to-eat lettuce is commercially packed under MAP conditions
of (2-5% O2, 5% CO2, 90% N2, balance N2), which reduces aerobic spoilage bacteria, thereby
increasing shelf life of the product. However, lettuce is a respiring vegetable that decreases the
oxygen level under MAP conditions, which has been shown to reach an anaerobic state after 7
days of storage (Hempel et al., 2013). Therefore, MAP conditions could potentially support the
persistence of anaerobic pathogens such as C. difficile, since previous research has revealed that
MAP conditions with low oxygen favor spore outgrowth and toxin production in Clostridium
botulinum (Kasai et al., 2005; Newell et al., 2012). Currently little information is available on the
viability characteristics of C. difficile on vegetables under MAP conditions. Therefore, this study
was undertaken to determine the viability of C. difficile spores on commercially available REL
under MAP conditions.
2. Materials and Methods
2.1 Sample collection and detection of C. difficile in REL
A total of 150 samples of REL were procured from geographically distant retail stores
(n=18) in Connecticut. All procured samples were brought to the laboratory on ice and processed
within 24 h. The detection of C. difficile was performed according to a previously published
protocol with modification for a higher detection limit (Weese et al., 2010). Twenty-five grams
of lettuce was separately added to 25 ml of C. difficile moxalactam-norfloxacin broth (Oxoid,
Hampshire, UK) supplemented with 0.1% sodium taurocholate (CDMNT) (Sigma-Aldrich, Inc.,
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St. Louis, MO, USA), and was subjected to stomaching for 1 min. After stomaching, 1 ml of broth
was pour-plated in duplicate in CDMNT agar, while the remaining broth-sample mixture was
incubated for enrichment in a Whitley A35 anaerobic workstation (Microbiology International,
Frederick, MD, USA) at 37°C for 48 h. After incubation, a 5 ml aliquot of the enriched sample
was subjected to alcohol shock by adding 5 ml of 100% anhydrous ethanol for 1 h to eliminate
vegetative C. difficile. The broth was subsequently centrifuged at 4000 x g for 10 min, and the
pellet was resuspended in 0.5 ml of sterile phosphate buffered saline (PBS, pH 7.0) and pourplated in CDMNT agar. The direct pour plates and enrichment pour plates were incubated
anaerobically at 37°C for 48 h. Presumptive C. difficile colonies were subcultured on 7% horse
blood agar and follow up identification of C. difficile was done based on growth in CDMNT agar,
Gram’s staining, and colony morphology characteristics. The identity of C. difficile was further
confirmed by L-proline aminopeptidase reaction (ProDisck, Remel, Lenexa, KS, USA) and PCR
targeting tpi, a species-specific housekeeping gene in C. difficile (Lemee et al., 2004).
2.2 Antibiotic susceptibility tests
The isolated C. difficile strains were tested for susceptibility to 10 antimicrobials
(ampicillin, cefoxitin, ciprofloxacin, clindamycin, erythromycin, metronidazole, moxifloxacin,
rifampicin, tetracycline and vancomycin) using E-test (bioMérieux, Marcy l'Etoile, France) on
Brucella blood agar supplemented with hemin and vitamin K, according to the manufacturer's
instructions. The plates were incubated for 48 h at 37°C under anaerobic conditions, after which
the minimum inhibitory concentration (MIC) values were determined. The MIC breakpoints for
clindamycin, metronidazole, moxifloxacin and vancomycin were compared with those established
by the CLSI (Clinical and Laboratory Standards Institute (CLSI), 2007), European Committee for
Antimicrobial Susceptibility Testing (EUCAST) and British Society of antimicrobial
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chemotherapy (BSAC) for C. difficile. For assessing the susceptibility to ampicillin, cefoxitin,
ciprofloxacin, clindamycin, erythromycin, rifampicin and tetracycline the epidemiological cutoff
values (ECOFF) recently established by the EUCAST obtained from the EUCAST MIC
distribution database were utilized (EUCAST, 2015). C. difficile toxigenic strain ATCC 1870 was
used as the control. The C. difficile isolates were considered multidrug resistant (MDR) if they
were resistant to three or more classes of antimicrobial agents (Schwarz et al., 2010; Thitaram et
al., 2016).
2.3 Toxin gene detection and ribotyping
A Chelex resin-based DNA extraction kit (InstaGene Matrix, Bio-Rad, France) was used
for extracting the genomic DNA from C. difficile isolates. A multiplex PCR was carried out to
detect the genes-encoding toxins TcdA and TcdB using previously published primers (Table 1)
(Antikainen et al., 2009). PCR amplification was done using HotstarTaq (Qiagen, Germantown,
MD, USA) PCR master mix, with thermocycler conditions: 10 min at 94°C, followed by 35 cycles
of 30 s at 94°C, 30 s at 60°C and 30 s at 72°C, with a final extension of 5 min at 72°C.
PCR ribotyping was performed using a previously published protocol (Bidet et al., 1999).
The amplification reactions with designed primers were performed using HotstarTaq PCR master
mix (Qiagen). The thermocycler conditions were 10 min at 94°C, followed by 35 cycles of 30 s
at 94°C, 30 s at 57°C and 30 s at 72°C, with a final extension of 5 min at 72°C. The PCR products
using the toxin gene primers were electrophoresed for 2 h at 75 V in 0.5X TBE using 1% agarose
gel (MidSci, St.Louis, MO, USA) stained with 0.5 µg/ml ethidium bromide, and analyzed under
UV light using the ChemiDoc MP Imaging System (Biorad, Hercules, CA, USA). The PCR
products using the ribotyping primers were electrophoresed for 10 h at 75 V in 0.5X TBE using
3% agarose gel stained with 0.5µg/ml ethidium bromide, and analyzed under UV light using the
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ChemiDoc MP Imaging System. The presence of bands from the toxin gene PCR and ribotype
profiles were analyzed with GelCompar II image analysis software (version 5.1; Applied Maths.,
Austin, TX, USA).
2.4 Spore preparation
C. difficile spores were prepared using a previously published protocol, with slight
modifications (Sorg & Dineen, 2009). Briefly, single colonies of ATCC BAA 1870, 1805 and
1053 were separately inoculated into Brain Heart Infusion broth supplemented with 5% yeast
extract (BHIS) (Oxoid) and cultured overnight at 37°C under anaerobic conditions. A 150 µl
aliquot of overnight culture was gently spread to evenly distribute the culture onto BHIS agar in
six-well plates, and incubated anaerobically for 7 days at 37°C in an anaerobic workstation
(Microbiology Inc, USA) to allow sporulation. After 7 days, spores were harvested from the wells
by flooding with 2 ml of ice cold sterile water. The spore suspension was heat treated at 60°C for
20 min to kill any vegetative cells, washed in dH2O and centrifuged at 16,000 g for 5 min with
five repeated washings and centrifugations to purify the spores. Spore suspensions were visualized
under a microscope to ensure 90% sporulation prior to storage at −20°C.
2.5 Lettuce inoculation
Spore suspensions generated from hypervirulent C. difficile strains ATCC BAA 1870,
1805 and 1053 were diluted in sterile water to obtain 2 log CFU/ml and 4 log CFU/ml inoculations.
An inoculum containing spores from the three C. difficile strains was prepared for each inoculation
level. Then 25 g of pre-cut fresh romaine lettuce was spot inoculated with 1 ml of inoculum in
droplets followed by drying under a laminar flow biosafety cabinet for 30 min (Chua et al., 2008;
Oliveira et al., 2010). Using sterile tongs, the inoculated lettuce was aseptically transferred to
vacuum sealable pouches with multilayer films designed for modified atmosphere packaging
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(Winpak, Winnipeg MB, Canada) and were flushed with a gaseous mixture of 2% O2, 5% CO2
and 93% N2 using an UltraSource ultra vac (UltraSource, Kansas City, MI, USA). Inoculated and
control MAP bags were immediately stored at 4°C for 10 days.
2.6 Enumeration of C. difficile and total bacteria on lettuce
The C. difficile populations on control and inoculated lettuce samples were enumerated on
days 0, 1, 3, 5, 7 and 10 of storage. Lettuce (25 grams) was diluted with 25 ml of sterile PBS and
was stomached for 2 min. The samples were serially diluted and pour-plated in duplicate on
CDMNT agar (Weese et al., 2010; Zhang et al., 2009). Plates were incubated at 37°C anaerobically
for up to 5 days before counting colonies. The samples were enriched by transferring 1 ml of the
PBS-lettuce to 9 ml of CDMNT broth for anaerobic incubation at 37°C for 48 h (Weese et al.,
2010), followed by pour-plating in duplicate on CDMNT agar, if no C. difficile was recovered by
direct plating. At each sampling time point, controls, 2 log CFU/ml and 4 log CFU/ml samples
were spread-plated in duplicate on plate count agar (PCA) for incubation at both 37°C and 4°C to
enumerate the total bacteria on the lettuce. The PCA plates were incubated at 37°C and 4°C, as
previously reported and counts were combined for the two temperature incubations to obtain a
total bacteria count for each sample (Akbas & Ölmez, 2007).
2.7 Statistical analysis
The required sample size for the prevalence study was determined using the PROCPOWER procedure of SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). A sample size of 150
samples was required to allow the detection of a difference in prevalence between 3% versus 14%
with an alpha = 0.05 and power = 0.80 (two-tailed test). All MAP experiments had duplicate
samples for each treatment, and the study was repeated three times. The data were analyzed using
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the PROC-MIXED procedure of SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Differences between the means were considered significantly different at p < 0.05.
3. Results and Discussion
A report from the US Centers for Disease Control and Prevention indicated that fresh
produce is responsible for the highest number of foodborne infections, accounting for ~ 46% of
the 9 million foodborne infections annually in the US (Painter et al., 2013). The high rate of
foodborne outbreaks linked to fresh produce may be due to the greater potential for pre-harvest
contamination from contaminated soil, irrigation water, improperly composted manure, farm
workers, or fecal run-off from domestic or wild animals (Buck et al., 2003; Mukherjee et al., 2007).
Hypervirulent C. difficile strains have also been isolated from soil, water, animal feces and
asymptomatic human carriers, thereby underscoring that they can potentially serve as sources of
C. difficile contamination on fresh produce (Himsworth et al., 2014; Janezic et al., 2016;
Rodriguez-Palacios et al., 2013; Xu et al., 2014). The isolation of C. difficile from REL could be
of greater concern than isolation from other foods since it is consumed raw. Moreover, REL is
packaged under modified atmosphere packaging (MAP) with limited oxygen, which favors the
persistence of anaerobic pathogens such as C. difficile. Previous research has revealed that MAP
conditions with low oxygen favor spore outgrowth and toxin production by C. botulinum (Kasai
et al., 2005; Newell et al., 2012). Moreover, potential temperature abuse of MAP-stored REL
during transport and retail storage could promote C. difficile spore germination and growth.
The prevalence rate of C. difficile in REL in Europe was found to be 2.9% in France
(Eckeert et al., 2013) and 7.5% in Scotland (Bakri et al., 2009; Eckert et al., 2013). The only
prevalence study in vegetables conducted in the US did not include REL (Rodriguez-Palacios et
al., 2014). In this study, we investigated the prevalence of C. difficile in 150 samples of REL from
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different retail stores in Connecticut. Presumptive colonies of C. difficile on selective CDMNT
agar were initially isolated from 35% of REL samples. Further testing of the presumptive colonies
with the L-proline aminopeptidase activity test decreased the number of positive samples to 30%.
However, PCR characterization to detect the housekeeping tpi gene, toxin genes, and ribotyping
pattern identified C. difficile in 23% (35/150) of REL samples. All 35 isolates were identified as
toxigenic by the presence of toxin genes tcdA and tcdB. Also, the ribotyping pattern of all 35 C.
difficile isolates matched the banding pattern of ribotype 027 (Fig. 1). Interestingly, all the REL
samples that tested positive for C. difficile were only by enrichment, and none of the samples
yielded colonies by direct plating.
We screened 20 of the 35 positive C. difficile isolates for resistance to ten antibiotics (Table
2) typically used in hospitals (Mooyottu et al., 2015). All of the isolates were found to be resistant
to ciprofloxacin (MIC > 32 μg/ml), erythromycin (MIC > 256 μg/ml) and moxifloxacin
(MIC > 32 μg/ml) (Table 2). Six of the isolates were found to be resistant to vancomycin
(MIC > 2 μg/ml). Moreover, the isolates were not susceptible to cefoxitin at the highest
concentration (MIC > 256 μg/ml). Also, the isolates were not resistant to clindamycin,
metronidazole, rifampicin or tetracycline (except for one isolate which was resistant to
metronidazole), with MIC values for clindamycin, metronidazole, rifampicin or tetracycline below
the ECOFF values of (16 μg/ml), (2 μg/ml), (0.004 μg/ml) and (0.25 μg/ml), respectively. The
MIC of ampicillin was found to be > 1.5 μg/ml in five of the isolates, which is not the defined MIC
for C. difficile, but is considered the MIC breakpoint for other Gram-positive anaerobes.
According to the Clinical and Laboratory Standards Institute (CLSI), bacterial isolates are
considered to be multi-drug resistant when exhibiting resistance to more than three groups of
antibiotics. American studies involving food animals, meat, and vegetables have reported
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resistance of C. difficile isolates to multiple classes of antibiotics (Harvey et al., 2011; RodriguezPalacios et al., 2013), especially with isolation of multidrug resistant C. difficile from food animals
and meat products (Peláez et al., 2013; Pirs et al., 2013; Thitaram et al., 2016). Similarly, our
results indicated that C. difficile isolates from REL samples were multi-drug resistant, exhibiting
resistance to ciprofloxacin, erythromycin and moxifloxacin. The presence of antimicrobial
resistance in C. difficile isolated from ready-to-eat vegetables has been identified in several
prevalence studies, where Bakri et al. (2009) and Rodriguez-Palacios et al. (2014) isolated C.
difficile strains resistant to moxifloxacin and clindamycin from Scotland and Ohio, respectively.
The C. difficile strains isolated in our study from REL were similarly resistant to moxifloxacin,
but were not resistant to clindamycin.
We conducted a follow-up study to determine the viability of C. difficile spores on REL
under MAP conditions used by the fresh produce industry (2% O2, 5% CO2 and 93% N2). Two
inoculation levels of 2.0 log CFU and 4.0 log CFU of C. difficile spores per gram of lettuce were
used in the survival study. Enumeration of viable C. difficile spore populations on selective
CDMNT agar on days 0, 1, 3, 5, 7 and 10 of refrigeration revealed that spores remained viable on
REL samples at both inoculation levels throughout storage (Fig. 2). The viability of C. difficile on
foods, including vegetables under modified atmosphere conditions has not been previously
investigated, although Jobstl et al. (2010) isolated C. difficile from a raw meat product packaged
under MAP conditions. This isolate was positive for the toxin producing genes, tcdA and tcdB and
was resistant to the antibiotics clindamycin and moxifloxacin (Jobstl et al., 2010).
Respiration of produce results in the decrease of oxygen content in a modified atmosphere
package, which could lead to an anaerobic environment during storage. The level of oxygen in
commercial control MAP conditions (5% O2, 5% CO2 and 90% N2) showed lack of oxygen after
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7 days of storage (Hempel et al., 2013). In addition, temperature abuse can speed up the respiration
rate of produce and lead to faster development of anaerobic conditions in MAP products, which
could be a concern for anaerobic pathogens (Francis et al., 1999). Clostridium botulinum, like C.
difficile, is an organism that has been isolated from the environment, including agricultural soils
in numerous countries (Huss, 1980), and has historically been studied for growth and toxin
production on vegetables packaged under MAP. Since the commercial gas mixture for MAP
contains low oxygen, which can be consumed by respiring produce, a potential concern for C.
difficile to grow and produce toxins exists if the packaging became anaerobic. A study on C.
botulinum in MAP packaged produce showed that toxins were produced by the bacterium at
temperatures of 15°C or higher, but growth and toxin production were controlled at temperatures
less than 5°C (Austin et al., 1998). The study showed that C. botulinum can survive in produce
packaged under MAP conditions, but will only grow and produce toxins under temperature abuse
conditions. Interestingly, these observations could be valid for C. difficile too, and results from our
study indicated that C. difficile spores remained viable at 4°C under MAP conditions, although
temperature abuse was not a focus here.
In conclusion, this study isolated C. difficile spores from 23% (35/150) of REL samples
procured from various retail stores in Connecticut. Although none of the positive samples yielded
any countable C. difficile populations by direct plating, the results are important, especially in light
of increasing REL consumption, particularly by vulnerable members of the population, including
the elderly, immunocompromised, and convalescent people in hospitals and nursing homes.
Therefore, further research is needed to determine if C. difficile spores could germinate and grow
in REL under temperature abuse conditions. Additionally, the potential role of REL in communityacquired C. difficile infection in humans requires additional investigation.
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Table 1. Primers used for PCR and Ribotyping.
Oligo name

Gene

Primer Sequence (5’-3’)

TPI-F1

tpi

AAAGAAGCTACTAAGGGTACAAA

Size (bp)
/position
230

TPI-R1
TA12

tcdA

CATAATATTGGGTCTATTCCTAC
ATGATAAGGCAACTTCAGTGG

624

TA22
TB12

tcdB

TAAGTTCCTCCTGCTCCATCAA
GAGCTGCTTCAATTGGAGAGA

412

tcdB

GTAACCTACTTTCATAACACCAG
GTGTAGCAATGAAAGTCCAAGTTTACGC

205

16S3

CACTTAGCTCTTTGATTGCTGCACCT
CTGGGGTGAAGTCGTAACAAGG

23S3

GGTACCTTAGATGTTTCAGTTC

TB22
NK 1042
NK 1052

(Lemee et al., 2004)1, (Antikainen et al., 2009)2, (Bidet et al., 1999)3
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21 (1445–
1466)
20 (1-20)

Fig 1. Ribotyping pattern of C. difficile isolates from lettuce.
The gel image shows multiplex polymerase chain reaction amplification products representing
ribotype banding patterns. Lane 1, 2: C. difficile ATCC 027, Lane 3: C. difficile ATCC 078, Lane
4: C. difficile ATCC 001, Lane 5, 6, 7, 8, 9: Representative REL isolates of C. difficile, Lane 10:
100 bp DNA ladder, Lane 11, 12, 13, 14, 16, 17, 18: Representative REL isolates of C. difficile,
Lane 19: Negative control, Lane 20: C. difficile ATCC 038.
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Table 2. Antibiotic sensitivity of C. difficile isolates to 10 clinically used antimicrobials

MIC
(ATCC
1870)
µg/ml

CLSI
break
point
µg/ml

Ampicillin
Cefoxitin

1
>256

Ciprofloxacin
Clindamycin
Erythromycin
Metronidazole
Moxifloxacin

Antibiotic

EUC
AST
ECO
FF

Minimum Inhibitory Concentration (MIC) µg/ml of lettuce isolates

(µg/
ml) <

Isolate
1

Isolate
2

Isolate
3

Isolate
4

Isolate
5

Isolate
6

Isolate
7

Isolate
8

Isolate
9

Isolate
10

-

-

0.75
>256

1.25
>256

1.5
>256

2
>256

1
>256

0.75
>256

1
>256

1.5
>256

1
>256

0.75
>256

>32
0.5
>256
0.19
>32

2
-

>32
2
>256
2
>32

>32
2
>256
3
>32

>32
8
>256
3
>32

>32
4
>256
1.5
>32

>32
4
>256
3
>32

>32
0.016
>256
0.38
>32

>32
3
>256
0.38
>32

>32
2
>256
0.5
>32

>32
0.75
>256
2
>32

>32
1.5
>256
0.25
>32

Rifampicin

0.002

-

0.002

0.003

0.003

0.002

0.002

0.003

0.002

0.002

0.002

<0.002

Tetracycline
Vancomycin

0.25
>256

>2

16
2
2
4
0.00
4
0.25
2

0.25
1

0.5
1.5

0.5
1

0.19
1

0.19
1.5

0.125
1

0.25
2

0.064
2

0.064
1.5

0.25
0.75
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MIC
(ATCC
1870)
µg/ml

CLSI
break
point
µg/ml

Ampicillin

1

Cefoxitin
Ciprofloxacin

Antibiotic

EUC
AST
ECO
FF

Minimum Inhibitory Concentration (MIC) µg/ml of lettuce isolates

(µg/
ml) <

Isolate
11

Isolate
12

Isolate
13

Isolate
14

Isolate
15

Isolate
16

Isolate
17

Isolate
18

Isolate
19

Isolate
20

-

-

2

2

0.75

1.5

2

1

1.5

2

0.5

1.75

>256
>32

-

-

>256
>32

>256
>32

>32
>256

>32
>256

>32
>256

>32
>256

>32
>256

>32
>256

>32
>256

>32
>256

Clindamycin
Erythromycin
Metronidazole
Moxifloxacin

0.5
>256
0.19
>32

2
-

6
>256
2
>32

3
>256
0.5
>32

0.5
>256
0.75
>32

0.75
>256
0.5
>32

1.5
>256
1.25
>32

1
>256
0.38
>32

0.75
>256
1.5
>32

0.125
>256
0.5
>32

0.016
>256
1
>32

1
>256
0.38
>32

Rifampicin

0.002

-

0.002

0.002

<0.002

0.003

0.002

0.002

0.002

0.002

<0.002

0.002

Tetracycline
Vancomycin

0.25
>256

>2

16
2
2
4
0.00
4
0.25
2

0.19
0.75

0.125
2

0.125
3

0.094
2

0.25
2

0.125
3

0.38
1.5

0.19
1.5

0.064
1

0.125
1.5
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Fig 2. Viability of C. difficile spores on REL under MAP during refrigerated storage.
C. difficile spores (ATCC BAA 1870, 1805 and 1053) at three inoculation levels; 0 log CFU/ml
(control), 2 log CFU/ml and 4 log CFU/ml. The C. difficile populations on lettuce for control and
inoculated samples were enumerated on days 0, 1, 3, 5, 7 and 10 by pour-plating CDMNT agar
with anaerobic incubation at 37°C for 48 h.
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Fig 3. Total bacteria on REL inoculated with C. difficile under MAP.
C. difficile spores (ATCC BAA 1870, 1805 and 1053) at three inoculation levels; 0 log CFU/ml
(control), 2 log CFU/ml and 4 log CFU/ml. Samples were serially diluted in PBS and spread plated
on PCA (plate count agar) to enumerate the total bacteria on lettuce on days 0, 1, 3, 5, 7 and 10.
PCA plates were incubated at 37°C and 4°C and counts were combined to determine total bacteria.
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Chapter IV
The effect of chilling, freezing and cooking on survivability of Clostridium difficile spores in
ground beef
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Abstract
Clostridium difficile is an anaerobic pathogen that causes serious infections in hospital
settings. However, recent trends have shown an increased incidence and severity of C. difficile
infections outside of hospital environments. In addition, human toxigenic C. difficile strains have
been isolated from food animals and animal-derived foods including ground meat, which suggests
potential foodborne transmission of C. difficile. Prevalence studies observing C. difficile in ground
beef in the US have isolated C. difficile in a range of 0 to 44%. This study investigated the effect
of chilling, freezing and the USDA recommended cooking temperature on survival of C. difficile
spores in ground beef.
A three-strain C. difficile spore suspension was inoculated at two levels (3 log CFU/g and
5 log CFU/g) in ground beef. Inoculated samples were separately subjected to chilling (4°C) for 1
week, freezing (-18°C) for 12 weeks, or cooking (71.1°C), after which viable spores were
enumerated at different time intervals. Similarly, total bacteria in ground beef was enumerated at
each time point by treatment.
Chilling for 1 week did not significantly affect the survival of C. difficile spores at both
levels of inoculation (p > 0.05). Similarly, freezing for 12 weeks did not significantly affect the
survival of C. difficile spores at both levels of inoculation in ground beef (p > 0.05). Freezing also
did not affect the viability of total bacteria in ground beef (p > 0.05). Cooking ground beef to the
USDA recommended temperature (71.1°C) decreased spore survival in ground beef inoculated
with 3 log CFU/g and 5 log CFU/g by 1 log CFU/g compared to uncooked controls (p < 0.05).
Our results suggest that C. difficile spores can survive chilling, freezing and cooking in
ground beef. The results warrant development of intervention strategies to control C. difficile
contamination of bovine carcasses.
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1. Introduction
Clostridium difficile is a spore-forming, nosocomial pathogen which causes a toxinmediated enteric disease in humans. The pathogen is responsible for over 500,000 cases and 29,000
deaths annually (Lessa et al., 2015), with $3 billion as health-care costs (O'Brien et al., 2007).
Although traditionally a nosocomial pathogen, recent trends have shown an increase in the
incidence and severity of C. difficile infections outside of hospital environments (Hensgens et al.,
2012; McDonald et al., 2006; Rupnik et al., 2009). It is reported that 32% of all C. difficile illnesses
in the United States are classified as community-associated C. difficile infections, especially in
individuals with no recent hospitalization (Lessa, 2013). This leads to concerns on the potential
sources of community associated C. difficile infections (Eyre et al., 2013). In addition, toxigenic
C. difficile strains have been isolated from foods and food animals which match human strains,
suggesting food as a potential source of C. difficile (Lessa et al., 2015; Thitaram et al., 2016).
The principal reservoir for C. difficile is the gastrointestinal tract of humans and warmblooded animals (Cato et al., 1986). In a USDA-APHIS study on the prevalence of C. difficile in
US cow-calf operations, C. difficile was isolated from 188 (6.3 percent) of 2,965 fecal samples
from apparently healthy beef cows. The study also reported that 76 of the 173 beef operations
(43.9 percent) yielded at least one positive sample. In a recent study by Bandelj et al. (2016), C.
difficile was detected with an average prevalence of 10% and 35.7% in cows and calves,
respectively (Bandelj et al., 2016). In another study conducted in the United States, C. difficile was
isolated with a prevalence rate of 25% in stool specimens collected from 253 diarrheic calves
(Hammitt et al., 2008). Likewise, in a study conducted in Canada, C. difficile was detected in
calves with a prevalence rates as high as 49% (Weese, 2010). In addition, human hypervirulent C.
difficile strain ribotype 027 has also been isolated from calves (Rodriguez-Palacios et al., 2006).
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If cattle are a source of C. difficile, beef could serve as a potential transmission route of the
pathogen from animals to humans. Results from several studies indicate that the overall prevalence
of C. difficile in ground beef in the US ranges from 0 to 44%, with a minimum of 23% of positive
isolates classified as toxigenic (Harvey et al., 2011; Houser et al., 2011; Limbago et al., 2012;
Mooyottu et al., 2015; Songer et al., 2009).
Clostridium difficile produces highly resistant spores, which can persist for long periods in
the environment (Fekety et al., 1981). Rodriguez-Palacios et al. (2016) observed that spores of 20
different strains of C. difficile survived the USDA-recommended meat cooking temperature of
71oC for 2 h in phosphate-buffered saline (PBS, pH 7). In addition, spores of hypervirulent C.
difficile strain 078 were reported to be resistant to sub-boiling temperatures (Rodriguez-Palacios
et al., 2016). This raises a significant food safety concern since heat tolerance studies with other
spore-formers such as C. perfringens suggest that heat resistance can be much higher in complex
food matrices such as ground meat than in buffer. Therefore, it is critical to understand C. difficile
susceptibility to common antimicrobial hurdles applied in foods, which are critical for developing
appropriate control measures. The objective of this study was to investigate the effect of chilling,
freezing and cooking on the survival of C. difficile spores in ground beef.
2. Materials and Methods
2.1 Spore preparation
Clostridium difficile spores were prepared using a previously published protocol, with slight
modifications (Sorg & Dineen, 2009). Three hyper virulent C. difficile isolates (ATCC BAA 1805,
1803 and 1053) were grown in brain heart infusion broth supplemented with 5% yeast extract
(BHI) (Difco, Sparks, MD, USA) in a Whitley A35 anaerobic work station (Microbiology Inc.,
USA) in the presence of 80% nitrogen, 10% carbon dioxide and 10% hydrogen at 37°C for 24 h.
The three-strain C. difficile culture (150 µl) was inoculated onto 6-well BHI agar plates followed
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by gentle rotation to evenly distribute the culture. After 7 d of incubation, when 90% sporulation
was visualized under a microscope, the spores were harvested from the wells. For collecting
spores, the wells were gently washed with 1 ml of sterile ice-cold water, after which the spore
suspension was transferred to tubes and subjected to centrifugation (14,000 rpm for 5 min at 4°C).
The supernatant was removed and the pellet was resuspended in 2 ml of sterile water.
Centrifugation and resuspension were repeated five times to remove cellular debris. The
resuspended spores were heat shocked at 60°C for 20 min to kill any remaining vegetative cells.
The spores were enumerated by serial dilution and plating on BHI agar supplemented with 0.1%
(w/v) sodium taurocholate (BHIS) (Sigma-Aldrich, Inc., St. Louis, MO, USA), followed by 48 h
of anaerobic incubation.
2.2 Sample preparation, chilling and freezing of ground beef inoculated with C. difficile
Ground beef samples were prepared according to a previously published method (Juneja et
al., 2013). Ten grams portions of 90% lean fresh ground beef were transferred to low oxygen
transmission Whirl-PakTM bags (Nasco, Ft. Atkinson, WI, USA). C. difficile spores were added to
ground beef to obtain 3 log CFU/g or 5 log CFU/g inoculation levels. Following the addition of
100 µl of spore inoculum, each ground beef sample was hand-mixed for 1 min and subjected to
stomaching for 1 min. The ground beef sample was flattened to a thickness of ~ 2 mm and bags
were sealed with a Foodsaver (Sunbeam Products Inc., Boca Raton, FL, USA). Ground beef
samples were either stored at 4°C for 7 days or frozen at -18°C for 12 weeks.
2.3 Enumeration of C. difficile spores and total bacteria in ground beef
Clostridium difficile spores were enumerated weekly from the frozen samples, and on days
0, 1, 3, 5 and 7 of storage in refrigerated meat (Weese et al., 2010). Frozen ground beef samples
were removed from the freezer and thawed for 1 hr. Ten grams of ground beef were mixed with
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20 ml of sterile PBS, and stomached for 1 min. The meat-PBS mixture was serially diluted and
1 ml portions were pour-plated in duplicate with C. difficile moxalactam-norfloxacin (Oxoid,
Hampshire, UK) agar supplemented with 0.1% (w/v) sodium taurocholate (CDMNT) and 7%
horse blood (Quad Five, Ryegate, MT, USA). In addition, 1 ml of the undiluted PBS-beef
homogenate was added to 9 ml of CDMNT broth for enrichment. The CDMNT agar plates and
enrichment broth were incubated anaerobically at 37°C for 48 h. After incubation, an aliquot of
the broth was subjected to alcohol shock by adding 100% anhydrous ethanol for 1 h to eliminate
vegetative bacteria. The broth was centrifuged at 4000 ×g for 10 min, and the pellet was
resuspended in 0.5 ml of PBS and pour-plated in CDMNT agar. The CDMNT agar plates were
incubated anaerobically at 37°C for 48 h. In addition, the total bacteria in ground beef was
enumerated by plating 100 µl of the serial dilutions of the PBS-beef mixture on tryptic soy agar
(TSA) with aerobic incubation at 37°C for 24 h (Dourou et al., 2011).
2.4 Sample preparation, and cooking of ground beef inoculated with C. difficile
Twenty-five gram portions of 90% lean ground beef were weighed. C. difficile spores were
prepared and 100 µl added to each 25-gram portion of ground beef to obtain an inoculation level
of 3 log CFU/g or 5 log CFU/g. Following this, the ground beef was hand-mixed for 1 min, and
formed into patties (Amalaradjou et al., 2010). The patties were cooked individually in a doublesided George Foreman Lean Mean Grilling Machine (Salton Inc., Columbia, MO, USA) until the
USDA recommended internal temperature for ground beef of 71.1°C was reached. A standard
meat thermometer (Acutuff Model 34 Atkins 2 mm probe meat thermometer, Koch Supplies) was
used to continuously monitor the internal temperature of patties. Each cooked patty was
immediately transferred to a Whirl-PakTM bag containing 50 ml of chilled CDMNT broth, followed
by hand-mixing and stomaching for 1 min. Uncooked patties were also transferred to Whirl-PakTM
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bags containing chilled CDMNT broth and subjected to stomaching for 1 min. After stomaching,
1 ml of the meat homogenate was pour-plated in duplicate CDMNT agar plates. Enrichment and
enumeration of samples was performed as previously described.
2.5 Statistical analysis
The freezing and chilling experiments included triplicate samples and the study was
repeated two times. The cooking experiment had triplicate samples and the study was repeated
three times. The data were analyzed using the PROC-GLM procedure of SAS v. 9.4 (SAS Institute
Inc., Cary, NC, USA). Differences between the means were considered significantly different at
p < 0.05.
3. Results & Discussion
C. difficile spores have been detected in water, soil, and animal feces (al Saif & Brazier,
1996; Rodriguez-Palacios et al., 2011), thereby potentially contaminating cattle hides and
carcasses during slaughter. Further, isolation of toxigenic C. difficile in beef cattle and ground
beef raises a concern on the potential meat-borne transmission of the pathogen to humans,
especially in light of the increasing number of community-associated C. difficile infections.
However, there is a paucity of information on the viability characteristics of C. difficile in meat,
or the effect of various meat processing treatments on C. difficile spores. Therefore, this study
investigated the effect of chilling, freezing and cooking on the viability of C. difficile spores in
ground beef.
Enrichment of uninoculated ground beef in CDMNT broth and subsequent plating on
CDMNT agar did not yield any C. difficile, thereby indicating the meat was devoid of the pathogen.
The survival of C. difficile spores during chilling and freezing was determined by a standard
quantitative method for enumeration on selective CDMNT agar (Weese et al., 2010). The effect
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of chilling on C. difficile spores in ground beef is depicted in Figure 1. Results indicated that
chilling for 1 week did not significantly affect the survival of C. difficile spores at either inoculation
level (p > 0.05). In ground beef inoculated with 3 log CFU of C. difficile spores/g of meat, a mean
spore population of ~ 2.50 log CFU/g was recovered on day 0, which remained the same
throughout storage (Fig. 1). Similarly, in ground beef samples inoculated with 5 log CFU of C.
difficile spores/g of meat, ~ 4.5 log CFU/g of spores were recovered on day 0, which did not
increase or decline during the entire storage period. However, the total bacteria in ground beef
samples inoculated with the two levels of C. difficile spores gradually increased from ~ 5.0 log
CFU/g on day 0 to 7 log CFU/g on day 7 (p < 0.05) (Fig. 2). This increase in total bacteria could
be attributed to the growth of psychrotrophic spoilage bacteria, which constitute the dominant
microflora in meat (Venkitanarayanan et al., 1996), however, this increase in psychrotrophic
bacteria had no inhibitory effect on C. difficile spores.
Freezing ground beef for 12 weeks did not significantly affect the viability of C. difficile
spores at either inoculation level (p > 0.05) (Fig. 3). Spore counts of ~ 2.47 log CFU/g and 4.32
log CFU/g were recovered on day 0 from the samples inoculated with 3 log CFU/g and 5 log
CFU/g, respectively, which remained the same throughout the storage period. In a very recent
study, Deng et al. (2015) evaluated the viability of spores of two C. difficile strains in PBS and a
meat model (in tube) during freezing, and reported a decreased spore viability in the meat model.
In one of the strains, a reduction in spore viability of 0.4 log CFU/ml (p < 0.05) from 6.7 to 6.3
log CFU/ml was observed after 2 months of freezing, whereas no significant (p > 0.05) decrease
in spore viability was identified in the second strain. The authors concluded that the meat matrix
may provide protection to C. difficile spores at low temperatures (Deng et al., 2015). In contrast
to these results, Lillard (1977) reported that freezing (-23°C) for 4 to 6 weeks significantly reduced
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the incidence and levels of C. perfringensspores in ground chicken. Further, no change in aerobic
bacteria was observed in our study during frozen storage (p > 0.05) (Fig. 4), which concurred with
the findings of Lillard (1977).
The effect of cooking on the viability of C. difficile spores in ground beef is shown in
Figure 5. At both low and high levels of inoculation, cooking beef patties to an internal
temperature of 71.1oC decreased spore counts only by 1 log CFU/g compared to uncooked controls
(p < 0.05) (Fig. 5). The USDA recommended internal cooking temperature of 71.1°C for ground
beef targets vegetative cells of foodborne pathogens such as E. coli O157:H7 and Salmonella
enterica (D'SA et al., 2000; USDA-FSI, 2006), but was ineffective in inactivating spores such as
spores produced by Bacillus cereus. Spores are survival structures which are resistant to dry and
wet heat because of the presence of protective exosporium layers in the inner and outer membranes
(Setlow & Johnson, 2013). Moreover, the thick outer coating in spores protects the internal DNA
against denaturation from heat, cold and other agents (Setlow, 2007). Previously, 71.1°C was
found to be inadequate for killing the spores of C. perfringens, C. botulinum and B. cereus (LuuThi et al., 2014; Peck et al., 2011; Sanchez-Plata et al., 2005).
In summary, results from this study indicate that chilling and freezing of ground beef do
not affect the survival of C. difficile spores. Further, cooking ground beef to the USDA
recommended internal temperature of 71.1°C resulted in only marginal reduction in C. difficile
spores. Therefore, effective intervention strategies should focus on control of C. difficile
contamination of bovine carcasses to reduce food-borne transmission of the pathogen.
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Figure 1. Effect of chilling (4°C) on survival of Clostridium difficile spores in ground beef.
Two C. difficile spore inoculums were prepared from a 3 strain mixture (ATCC BAA 1805, 1803
and 1053) and inoculated at 2 levels (3 log CFU/g and 5 log CFU/g) in ground beef. Clostridium
difficile was enumerated during refrigeration storage (4°C) on days 0, 1, 3, 5 and 7 by pour-plating
on CDMNT agar with anaerobic incubation at 37°C for 48 h. Superscripts (a) and (b) denote no
significant difference among means within an inoculation group.
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Figure 2. Viability of total bacteria in ground beef stored at 4°C for 7 days.
Viability of total bacteria in ground beef was determined on days 0, 1, 3, 5 and 7 by plating on
tryptic soy agar. Superscripts (a, b, c, d, a’, b’, c’ and d’) denote a significant difference among
means within an inoculation group.
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Figure 3. Effect of freezing (-18°C) on survival of C. difficile spores in ground beef.
Two C. difficile spore inoculums were prepared from a 3 strain mixture (ATCC BAA 1805, 1803
and 1053) and inoculated at 2 levels (3 log CFU/g and 5 log CFU/g) in ground beef. Clostridium
difficile was enumerated during freezing storage on weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
by pour-plating on CDMNT agar with anaerobic incubation at 37°C for 48 h. Superscripts (a) and
(b) denote no significant difference among means within an inoculation group.
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Figure 4. Total bacteria in ground beef stored at -18°C for 12 weeks
Total bacteria in ground beef were enumerated on weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
of frozen storage by plating on tryptic soy agar. Superscripts (a) and (b) denote no significant
difference among means within an inoculation group.
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Figure 5. Effect of cooking (71.1°C) on C. difficile spores in ground beef patties
Ground beef patties were inoculated with a three-strain C. difficile spore mixture of 3 log CFU/g
and 5 log CFU/g. The patties were cooked individually to the USDA recommended internal
temperature for meat of 71.1°C. The cooked patties were immediately transferred to a Whirl-PakTM
bag containing 50 ml of chilled CDMNT broth, mixed and pour-plated for enumeration on
CDMNT agar. Superscripts (a, b, c and d) denote a significant difference in the means among the
treatments within an inoculation group.
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Chapter V
Viability of Clostridium difficile spores in fermented pork summer sausage
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Abstract
Clostridium difficile is a spore-forming pathogen, which is transmitted through the fecaloral route, and causes a severe disease in humans. Hypervirulent strains of C. difficile have been
isolated from a variety of food animals and meat, including pork. Pork summer sausage is a popular
fermented and cooked/partially cooked meat product in the US, which is consumed cold. A lower
cook temperature (internal temperature ≤ 57°C) can be used due to acidification of the product
from bacterial fermentation. However, the effect of acidity and cooking on the viability of C.
difficile spores in a fermented meat product has not been determined. Therefore, this study
investigated the effect of fermentation and cooking on the survival of C. difficile spores in pork
summer sausage.
Fermented pork sausages were prepared according to a commercially used recipe, where
fresh ground pork (90% lean) was combined with salt (2.25%), spice mix, dextrose, starter culture
(Pediococcus acidilactici, 7 log CFU/g), and inoculated with C. difficile spores (5 log CFU/g).
Control unfermented sausages included all ingredients except the starter culture. The sausages
were fermented at 37°C for ~ 12 h under 85% RH until the internal meat pH reached 5.0. Both
fermented and unfermented sausages were either cooked to an internal temperature of 66.5°C for
45 min (cooked group) or were uncooked. The sausages were sealed in Whirl-PakTM bags, cooled
and stored at 4°C. Viable C. difficile spores in sausages were enumerated at 1 h following
inoculation, and on days 0, 1, 7, 14, 21, 30 and 60 of storage. Triplicate samples of sausages were
included, and the study was replicated three times.
C. difficile spores remained viable in all treatment groups. C. difficile spore viability in
control unfermented treatment was significantly different on day 0 from the fermented, fermented
cooked and control unfermented cooked treatments (p < 0.05) however, there was no significant

93

difference among the latter three treatment groups throughout 90 days of storage (p > 0.05). On
day 90 of storage, the unfermented control sausages yielded ~ 4.0 log CFU/g of C. difficile spores
compared to ~ 3.5 log CFU/g recovered from fermented samples and the unfermented cooked
control samples identifying spore viability in all treatment groups. Therefore, results suggest that
C. difficile spores can survive the acidity and cooking typically encountered in fermented pork
summer sausage, thereby highlighting the need for effective intervention strategies to control C.
difficile contamination of pork carcasses, and its persistence in pork products.
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1. Introduction
Clostridium difficile is a Gram positive, anaerobic nosocomial pathogen which causes a
serious and potentially life-threatening toxin-mediated disease. The infection is characterized by
abdominal pain and diarrhea, leading to more serious clinical manifestations such as colitis and
toxic megacolon (Postma et al., 2015). Although traditionally regarded as a nosocomial infection,
especially in those receiving antimicrobial therapy (Evans & Safdar, 2015; Hookman & Barkin,
2007; Lessa et al., 2015), a new epidemiological trend observed in C. difficile incidence is an
increase in the number and severity of infections in humans, particularly those involving
communities outside the hospital environment (Desai et al., 2016; Deshpande et al., 2013; Galdys
et al., 2014). Further, C. difficile infections have been increasingly diagnosed in low risk
individuals, who are younger with no history of receiving antibiotic treatment (Dumyati et al.,
2012). Many investigators have reported the occurrence of C. difficile in a variety of food animals,
and one of the reasons attributed to the increased reports of human C. difficile infections is the rise
in isolation rates of the pathogen from animal reservoirs (Indra et al., 2009; Rupnik et al., 2008).
C. difficile has been isolated from raw and ready-to-eat meats intended for human consumption at
retail stores (Mooyottu et al., 2015; Rodriguez-Palacios et al., 2013; Rupnik & Songer, 2010). The
detection of genotypically similar and identical C. difficile strains implicated from human
infections in food animals and foods (Bauer & Kuijper, 2015; Rodriguez-Palacios et al., 2007;
Weese, 2010) further strengthens the potential role of food as a source of community-associated
C. difficile infection (Jhung et al., 2008; Kuijper et al., 2006; Songer et al., 2009).
C. difficile is a major cause of enteritis in neonatal pigs (Knight et al., 2015; Norén et al.,
2014), and has been reported to cause significant mortality in suckling piglets (Songer &
Anderson, 2006). C. difficile has also been isolated from live adult pigs at rates between 0 and
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23%, with a high colonization rate in sows around the time of farrowing (Thakur et al., 2011;
Weese, 2010). In a study involving 600 piglets with enteritis, Songer & Uzal (2005) observed that
35% of the animals were infected with C. difficile (Songer & Uzal, 2005). In another study, while
examining 2000 piglets with enteritis, Songer & Anderson (2006) reported C. difficile in more than
one-third of the animals, and concluded that C. difficile is potentially the most significant
uncontrolled cause of neonatal diarrhea in pigs (Songer & Anderson, 2006). With swine being a
potential reservoir of C. difficile, contamination of swine carcasses at the time of slaughter could
lead to downstream contamination of pork and other ready-to-eat (RTE) pork products. A survey
involving three sausage processing plants in Texas and five retail meat locations isolated C.
difficile from 9.5% (23/243) of meat samples and swab samples collected over a five-year period
(Harvey et al., 2011). Another prevalence study conducted in the US found that 62.5% of the RTE
pork braunschweiger tested were positive for C. difficile (Songer et al., 2009). In addition, Wu et
al. (2017) recently identified toxigenic C. difficile isolates in (3/15) ready-to-eat pork products,
braised skin and braised colon, which were cooked to 100°C for 30 min (Wu et al., 2017). Thus,
in light of C. difficile isolation in live pigs, processing facilities and retail pork products, there
exists a potential risk of C. difficile contamination in RTE pork products.
Pork summer sausage is a popular fermented meat product in the US, and can be classified
as cooked (internal temperature > 57°C), or uncooked to a lower temperature (internal temperature
≤ 57°C), since acidification due to fermentation is believed to kill any surviving pathogens in the
product (Calicioglu et al., 1997; USDA FSIS, 2013). The starter culture, Pediococcus acidilactici,
is commonly used in fermented sausage to produce lactic acid as a by-product of fermentation,
which in turn lowers the product pH. If C. difficile spores could survive the pH and cooking
temperature employed in fermented pork summer sausage, this RTE product could be a potential
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source of the pathogen. Since, no previous research investigated the viability of C. difficile spores
in any fermented meat product, the viability of C. difficile spores in RTE fermented pork summer
sausage was determined.
2. Materials and Methods
2.1 Spore preparation
C. difficile spores were prepared using a previously published protocol with slight
modifications (Sorg & Dineen, 2009). Briefly, single colonies of C. difficile ATCC BAA 1805,
1803 and 1053 were separately inoculated into Brain Heart Infusion broth supplemented with 5%
yeast extract (BHIS) (Oxoid, Hampshire, UK), and cultured overnight at 37°C under anaerobic
conditions. A 150 µl aliquot of overnight culture was gently spread to evenly distribute the culture
onto BHIS agar (Oxoid) in six well plates and was cultured anaerobically for 7 days at 37°C in a
Whitley A35 anaerobic workstation (Microbiology International, Frederick, MD, USA) to allow
sporulation. After 7 days, spores were harvested from the wells by flooding 2 ml of ice cold sterile
water. The spore suspension was heat treated at 60°C for 20 min to kill any vegetative cells, and
was washed five times in sterile dH2O by centrifuging at 16,000 g for 5 min. Spore suspensions
were visualized under a microscope to ensure 90% sporulation prior to storage at −20°C.
2.2 Sausage preparation and fermentation
Fermented pork sausages were prepared according to a published protocol (Baccus-Taylor
et al., 1993; Vignolo et al., 2010). Pork (90% lean) was hand-mixed with the addition of sterile
deionized water, salt (2.25%), summer sausage spice mix (Sausage Maker, Buffalo, NY, USA),
sodium erythorbate (Sigma-Aldrich, St. Louis, MO, USA), curing salt and dextrose (SigmaAldrich). Following the addition of C. difficile spores (5 log CFU/g of pork batter) and starter
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culture, P. acidilactici at 7 log CFU/g (SAGATM 200 Kerry Ingredients and Flavours, Rochester,
MN, USA), ground pork was hand-mixed, and subsequently minced with a manual grinder
(Weston, Strongsville, OH, USA) using a 3/8” grinding plate. A sausage formulation, including
all ingredients except P. acidilactici was included as an unfermented control. The ground pork
mixture was stuffed into synthetic casings (Nojax® Casings 13/16” provided by Viskase, Darien,
IL, USA) using a jerky gun with a 10 mm stuffing horn (LEM, West Chester, OH, USA). Sausages
were fermented at 37°C for ~ 12 h under 85% RH until the internal meat pH reached 5.0. A Caron
humidity controlled incubator (Caron Products, Marietta, OH, USA) was utilized for fermentation
to maintain 37°C and 85% RH. The fermented group of sausages were fermented to pH 5.0 and
cooled by transferring to individual gas-impermeable Whirl-PakTM bags and submerging in ice
cold sterile deionized water, followed by sealing and storage at 4°C. One-half of the fermented
sausages were immediately transferred to a drying oven (VWR, Radnor, PA, USA ) set to 100°C
for cooking to an internal temperature of 66.5°C for ~ 45 min, where temperature was continuously
monitored using a digital thermocouple (Oakton Instruments, Vernon Hills, IL, USA) inserted
internally in the sausage. Fermented cooked sausages were then cooled by transferring to
individual gas-impermeable Whirl-PakTM bags and submerging in ice cold sterile deionized water
for refrigerated storage. The control unfermented group of sausages were also stored at 37°C for
~ 12 h under 85% RH, and subjected to cooking as before or uncooked, and subsequently stored
in gas-impermeable Whirl-PakTM bags at 4°C.
2.3 Bacterial enumeration
Three sausages were analyzed for pH, water activity (aw), viable C. difficile spores and P.
acidilactici populations at 1 h following inoculation, and on days 0, 1, 7, 14, 21, 30, 60 and 90 of
refrigerated storage. Each sausage was removed from its casing, and both the casing and sausage
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were together added to a Whirl- PakTM bag containing 10 ml of phosphate-buffered saline (PBS
pH 7.0), and subjected to stomaching for one min. After stomaching, 1 ml of the sausage
homogenate was pour-plated in duplicate with Clostridium difficile moxalactam norfloxacin agar
supplemented with 0.1% sodium taurocholate (CDMNT). The plates were incubated anaerobically
at 37°C for 48 h. In addition, 1 ml of the homogenate was added to 9 ml of CDMNT broth and
incubated for enrichment. Following enrichment, a 5 ml aliquot of the broth was subjected to
alcohol shock by adding 5 ml of 100% anhydrous ethanol for 1 h to eliminate vegetative bacteria.
The broth was subsequently subjected to centrifugation at 4000 x g for 10 min, and the pellet was
resuspended in 0.5 ml of PBS and pour plated with CDMNT agar. The CDMNT agar plates were
incubated anaerobically at 37°C for 48 h. Moreover, the population of P. acidilactici present in
each sausage sample was enumerated at each time point by plating on de Main Rogosa and Sharpe
agar (MRS) (Oxoid) with incubation at 37°C for 48 h (Casquete et al., 2011).
The pH and aw of the fermented summer sausages were measured as described by Hristo
et al. (2013) (Hristo et al., 2013). Briefly, pH was determined at 25oC by inserting a pre-calibrated
pH meter probe (Thermo Fisher Scientific, Waltham, MA, USA) directly into three sausages from
each treatment group. For measuring aw at room temperature (25oC), a calibrated water activity
meter (Rotronic, Hauppauge, NY, USA) was used and sausage samples from each treatment group
were cut into small pieces and placed in a plastic sample cup. The bottom of the cups were
completely covered with sausage sample, placed in the water activity meter and readings were
recorded following humidity and temperature stabilization of the instrument.
2.4 Statistical analysis
All experiments included triplicate samples for each treatment, and the study was
repeated three times. The data were analyzed using the PROC-GLIMMEX procedure of SAS
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version 9.4 (SAS Institute Inc., Cary, NC, USA). Differences between the means were
considered significantly different at p < 0.05.
3. Results and Discussion
Hypervirulent Clostridium difficile isolates have been detected in live pigs, pork sausage
manufacturing plants, and retail pork products. Pork summer sausage is consumed cooked (internal
temperature > 57°C), or cooked to a lower temperature (internal temperature ≤ 57°C) since low
pH resulting from fermentation is believed to kill pathogens (Calicioglu et al., 1997; USDA FSIS,
2013). However, the effect of heat and acidity on the viability of C. difficile spores in a fermented
meat product has not been previously investigated. Therefore, this study determined the survival
of C. difficile spores in pork summer sausage, which is a popular fermented RTE product in the
US.
Results revealed that C. difficile spores remained viable under an acidic pH of 5.0 in
fermented pork summer sausage during three months of refrigerated storage. C. difficile spores
remained viable in all treatment groups. C. difficile spore viability in control unfermented
treatment was significantly different at day 0 from the fermented, fermented cooked and control
unfermented cooked treatments (p < 0.05) however, there was no significant difference among the
latter three treatment groups throughout 90 days of storage (p > 0.05) (Fig. 1). On day 90 of
storage, the control unfermented sausages yielded ~ 4.0 log CFU/g of C. difficile spores compared
to ~ 3.5 log CFU/g recovered from fermented samples and the control unfermented cooked
samples identifying spore viability in all treatment groups. Pediococcus acidilactici counts in the
fermented group remained at ~ 7.5 log CFU/g throughout 90 days of storage, but declined in the
fermented cooked group from day 21 reaching ~ 2 log CFU/g by the end of storage (Fig. 2). The
pH of control unfermented sausage was 5.68 on day 0 and did not significantly change over 90
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days of storage (Table 1). The pH of control unfermented cooked sausages was 5.73 on day 0,
which significantly increased to 6.08 by the end of the storage period (p < 0.05). The pH of the
unfermented sausage groups was consistent with agriculture standards for pork meat (Ministry of
Agriculture, 2001). On the other hand, as expected, the pH of fermented sausages was ~ 4.8 on
day 0, where it increased to 5.04 and 5.31 (p < 0.05) on day 90 in uncooked and cooked samples,
respectively. The significant increase in pH observed in cooked fermented sausages is consistent
with a previous study, where a significant increase in pH of cooked sausages from 4.75 to 4.84
was observed over 8 weeks of storage (Tremonte et al., 2005). Also, no significant difference in
aw was observed between control and fermented treatment groups during 90 days of storage (p >
0.05) (Table 2); the fermented cooked samples yielded the lowest aw of 0.889 on day 90 of storage.
The USDA guidelines for meat fermentation are based on literature evaluating pH and
temperature parameters for controlling pathogens such as Escherichia coli O157:H7 (USDA FSIS,
2013). A pivotal study on the fate of E. coli 0157:H7 in fermented summer sausage identified that
a 5-log reduction in pathogen counts can be achieved with fermentation to a final pH of 5.0,
followed by heating to an internal temperature of 54°C for 30 min, and a 7-log reduction in counts
with heating for 60 min at 54°C (Calicioglu et al., 1997). However, the results from this study
revealed that C. difficile remained viable in pork summer sausage despite achieving the
aforementioned pH and even higher cooking temperature.

This could be attributed to the

differences in the heat and acid resistance between the vegetative cells of E. coli O157:H7 and C.
difficile spores. Although the effect of heat and acidity on the viability of C. difficile spores in meat
has not been investigated, Rodriguez-Palacios et al. (2010) reported that C. difficile vegetative
cells survived the USDA-recommended meat cooking temperature of 71oC for 2 hours in
phosphate buffered saline (Rodriguez-Palacios et al., 2010). Thus, C. difficile spores are expected
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to survive the acidity and cooking commonly employed in fermented pork summer sausage,
thereby highlighting the need for effective intervention strategies to reduce spore contamination
or viability in RTE meat products.
Many RTE meats, including fermented sausages, which are not heated, or heated to a lower
internal temperature, contain preservatives to control spoilage bacteria and foodborne pathogens.
Sodium nitrite is a preservative commonly used to control C. botulinum spores as well as spoilage
bacteria in RTE cured meat (Hospital et al., 2016; Xi et al., 2011). However, a recent study reported
that even vegetative cells of C. difficile are resistant to the USDA recommended levels of nitrite
(200 ppm) and nitrate (500 ppm) in RTE meat products (Lim et al., 2015). The study also noted
that the use of both preservatives together did not exert a synergistic effect against C. difficile. It
is highlighted that this study was conducted with vegetative C. difficile, and spores being more
resistant than vegetative cells to antimicrobials, it is logical to conclude that nitrites and nitrates
would not kill C. difficile spores if present in RTE meat products.
The aforementioned results documenting the resistance of C. difficile spores to a commonly
used preservative in RTE meat along with our results showing the survival of C. difficile spores
under a pH of 5.0 and cooking temperature of 66.5°C for 45 min in fermented sausages, underscore
the potential risk of the pathogen in RTE meat. Therefore, additional research is required to further
investigate the prevalence of C. difficile in RTE meat and fermented meat products. Moreover,
effective intervention strategies to control C. difficile in live pigs and pork carcasses are critical to
reduce food-borne transmission of the pathogen.
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Figure 1. Viability of C. difficile spores in fermented pork sausage.
C. difficile strains were grown under anaerobic conditions for 10 days after which spores were
harvested. Fermented pork sausages were prepared according to a commercially used recipe,
where fresh ground pork (90% lean) was added with salt (2.25%), spice mix, dextrose, starter
culture (P. acidilactici, 7 log CFU/g) and C. difficile spores (5 log CFU/g) strains (ATCC 1805,
1803 and 1053). Control unfermented sausages included all ingredients except the starter culture.
The sausages were fermented at 37°C for 12 h under 85% RH until the internal meat reached pH
5.0. Both fermented and unfermented sausages were either cooked to an internal temperature of
66.5°C for 45 min or uncooked. Viable C. difficile spores in sausages were enumerated on
CDMNT agar at 1 h and on days 0, 1, 7, 14, 21, 30 and 60 of storage at 4°C.
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Figure 2. Pediococcus acidilactici populations recovered from fermented pork sausage
during storage.
Fermented pork sausages were prepared according to a commercially used recipe, where fresh
ground pork (90% lean) was added with salt (2.25%), spice mix, dextrose, starter culture (P.
acidilactici, 7 log CFU/g) and C. difficile spores (5 log CFU/g). P. acidilactici counts were
enumerated on MRS agar on days 0, 1, 7, 14, 21, 30 and 60 of storage at 4°C.
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Table 1. Average pH of fermented and unfermented pork sausage with and without
cooking.
Control
Unfermented

Control
Fermented
Fermented
Unfermented
Cooked
Cooked
Day 0
5.68
5.73
4.80
4.81
Day 1
5.69
5.89*
4.92*
5.05*
Day 7
5.73
5.94*
4.74
5.02*
Day 14
5.81*
5.99*
4.65*
5.06*
Day 21
5.61
6.00*
4.72
5.15*
Day 30
5.58
6.10*
4.72
5.19*
Day 60
5.39*
6.19*
4.73
5.32*
Day 90
5.61
6.08*
5.04*
5.31*
* Significant difference between day 0 and sampling day within a treatment group (p < 0.05)
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Table 2. Water activity measured at 25°C of fermented and unfermented pork sausage
with and without cooking.
Control
Unfermented
Day 0
Day 1
Day 7
Day 14
Day 21
Day 30
Day 60
Day 90

0.936
0.938
0.937
0.935
0.925
0.926
0.925
0.929

Control
Fermented
Unfermented
Cooked
0.910
0.938
0.941
0.944
0.898
0.919
0.908
0.919
0.901
0.929
0.900
0.887
0.912
0.930
0.905
0.935
*No significant difference (p > 0.05)
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Fermented
Cooked
0.898
0.907
0.902
0.883
0.870
0.886
0.908
0.889

Chapter VI
Efficacy of octenidine hydrochloride (OH) in reducing Clostridium difficile spores on
stainless steel surfaces
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Abstract
Clostridium difficile is a spore-forming nosocomial pathogen which causes a toxinmediated enteric infection in humans. The spores of C. difficile can survive on abiotic surfaces for
several months, and act as a source of new and recurrent infections by a fecal-oral route. This study
investigated the sporicidal efficacy of octenidine hydrochloride (OH), a new generation
disinfectant, against C. difficile spores on stainless steel surfaces. Suspensions containing 106
hyper-virulent C. difficile (ATCC 1870 and 1805) spores/ml were inoculated on stainless steel
discs (16 mm diameter) and treated with 0%, 1%, 2%, 3%, 4% and 5% of OH in ethanol for 10
min. Viable attached spores were recovered from the discs and enumerated by pour plating. In
addition, discs were inoculated with different levels of C. difficile spores/ml (105, 104, 103 and
102), and wiped with 1%, 3% and 5% of OH, followed by enumeration of residual spores on the
discs and wipes. Octenidine hydrochloride decreased C. difficile spores on steel discs (p < 0.05).
In C. difficile strains ATCC 1870 and 1805, 5% OH decreased spores by ~ 2.5 log CFU/ml
compared to controls. Similarly, wiping with OH reduced C. difficile spores on stainless steel
surfaces by up to 4 log CFU/disc compared to controls. Additionally, more than a 4 log reduction
in residual spores was found on wipes treated with 5% OH (p < 0.05). The results suggest that OH
could potentially be used as a disinfectant to reduce C. difficile spores on stainless steel surfaces.
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1. Introduction
Clostridium difficile is a gram-positive, spore forming anaerobic pathogen, which causes a
serious enteric disease in humans (Hookman & Barkin, 2009). Annually, over 500,000 cases of C.
difficile infections (CDI) are reported in the United States, which incur ~ $3 billion in healthcare
and treatment costs (Lessa et al., 2015; Lucado et al., 2012). Clostridium difficile infections are
transmitted through a fecal-oral route, and the majority of cases occur in healthcare facilities
(McFarland et al., 1989). Ingested C. difficile spores germinate in the intestine of susceptible
individuals and cause toxin-mediated colitis and diarrhea (Hookman & Barkin, 2009; Kuehne et
al., 2011). Infected patients shed highly resistant spores in their feces and contaminate the
environment. These spores can survive on abiotic surfaces for up to 5 months (Dubberke et al.,
2008; Hasan et al., 2011; Kramer et al., 2006). Commonly contaminated hospital surfaces and
equipment include; floors, call buttons, windowsills, bedrails, toilets, bedside-tables,
thermometers, commodes, blood-pressure cuffs, and intravenous catheters (Dubberke et al., 2008;
Gerding et al., 2008; Guerrero et al., 2012). In addition, transmission through hands can occur
when healthcare workers or patients come in contact with surfaces contaminated with C. difficile
spores (Guerrero et al., 2012; Weber et al., 2010). An observational study including 30 patients
with C. difficile found a 50% transfer rate on gloved hands following health-care worker
examination of patient skin sites (chest, hand, abdomen and arm). This study also observed greater
than a 50% transfer rate to health-care workers gloved hands after touching hospital surfaces such
as call buttons, bed rails and tables (Guerrero et al., 2012). Therefore, it is critical for hospitals to
establish a routine and effective disinfection procedure against C. difficile spores to control
transmission. Commonly used hospital disinfection agents, such as quaternary ammonium-based
and other surfactant-based detergents do not kill C. difficile spores, and may increase sporulation
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capacity (Gerding et al., 2008; Kelly & LaMont, 2008; Nerandzic & Donskey, 2016). Currently,
the only disinfectant recommended for use during C. difficile outbreaks is 1:10 sodium
hypochlorite solution with 10 min of contact time (Cohen et al., 2010; Fawley et al., 2007). This
high concentration can cause skin irritation and respiratory distress in healthcare workers and
patients, and lead to corrosion of hospital surfaces and equipment (Barbut et al., 2009; Keward,
2013). Thus, there is a critical need for a safe and effective alternative disinfectant that can be used
routinely against C. difficile in hospitals.
Octenidine hydrochloride (OH) is a bispyridinamine compound that has two active cation
centers which bind to negatively charged components such as cardiolipin in bacterial cell
membranes (Brill et al., 2006; Harke, 1989). Since human cell walls do not contain cardiolipin,
OH does not bind to eukaryotic cells, which makes the compound safe for use on skin and wounds
(Harke, 1989; Lademann et al., 2012). The compound has a broad spectrum of activity against
Gram-positive and Gram-negative bacteria (Bailey et al., 1984; Hubner et al., 2010; Lademann et
al., 2012; Sedlock & Bailey, 1985). It is used as an antiseptic on skin and wounds which identifies
its safety as a routine disinfectant (Hirsch et al., 2009; Lademann et al., 2012; Tietz et al., 2005).
Further, OH has proven effective in reducing the number of bacterial pathogens on wounds such
as Acinetobacter baumannii, Staphylococcus aureus, Staphylococcus epidermidis and Proteus
mirabilis (Lademann et al., 2012; Selçuk et al., 2012; Sopata et al., 2008). Further, OH is used as
a mouthwash, and was shown to eliminate plaque-forming microorganisms, including
Streptococcus mutans (Bailey et al., 1984; Beiswanger et al., 1990; Dogan et al., 2008; Rohrer et
al., 2010). In addition, OH showed antimicrobial effectiveness against planktonic cells and
biofilms of Listeria monocytogenes, Staphylococcus aureus and multi-drug resistant A. baumannii
(Amalaradjou & Venkitanarayanan, 2014; Amalaradjou et al., 2009; Junka et al., 2014; Narayanan
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et al., 2016). Moreover, it has been observed that the development of bacterial resistance against
OH is minimal, and based on animal studies, OH is neither carcinogenic nor mutagenic (Al-Doori
et al., 2007; Hirsch et al., 2009). In this study, we investigated the efficacy of OH for reducing C.
difficile spores on stainless steel surfaces for its potential use as a routine disinfectant in hospitals
to reduce CDI transmission.
2. Materials and Methods
2.1 Spore preparation
Clostridium difficile spores were prepared using a previously published protocol with slight
modifications (Sorg & Dineen, 2009). Two hypervirulent C. difficile isolates (ATCC BAA 1870
and 1805) were grown in brain heart infusion broth (BHI) supplemented with 5% yeast extract
(Difco, Sparks, MD, USA) in a Whitley A35 anaerobic work station (Microbiology Inc., Frederick,
MD, USA) in the presence of 80% nitrogen, 10% carbon dioxide and 10% hydrogen at 37oC for
24 h. The cultures were inoculated onto 6-well BHI agar plates by adding 150 µl of each culture
separately followed by gentle rotation to evenly disperse the culture. After 7 days of incubation, a
loopful of colony was taken for Gram staining. When 90% sporulation was visualized under a
microscope, the spores were harvested from the wells as follows.
The wells of the 6-well plate were flooded and gently washed with 1 ml of sterile ice-cold
phosphate-buffered saline (PBS). Following washing, the spore suspension was transferred to
tubes for sedimentation by centrifugation (14,000 rpm for 5 min, 4°C). The supernatant was
removed with a pipette and the pellet was resuspended in 2 ml of sterile PBS. Centrifugation and
resuspension were repeated 5 times to remove cellular debris. The resuspended spores were heatshocked at 60°C for 20 min to kill any remaining vegetative cells. The spores were enumerated by
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serial dilution and plating on brain heart infusion agar supplemented with 0.1% (w/v) sodium
taurocholate (BHIT) (Thermo Fisher Scientiﬁc, Pittsburg, PA, USA). The plates were incubated
anaerobically for 48 h and colonies enumerated. The spore solution was divided into aliquots and
diluted to 1.0 x 107 spores/ml. The spore stock was then stored at -80°C.
2.2 Sporicidal efficacy of OH against C. difficile on stainless steel surfaces
This test procedure was based on the American Society of Testing Materials (ASTM) E2197
– 11 method for assessing the effect of a treatment on bacterial contamination (Boyce et al., 2011).
Stainless steel discs (16 mm diameter) were placed in a 12-well plate. The surface of each disc
was inoculated with 100 µl of spore solution containing ~106 spores. The inoculum was air dried
at room temperature for 1 h. The disc treatments were as follows; an untreated control of C. difficile
inoculation alone, an ethanol control, and 5 treatments with 1%, 2%, 3%, 4%, or 5% OH. The
treatments were added at a volume of 1 ml to fully submerge the disc and incubated at room
temperature for 10 min. The discs were transferred aseptically with sterilized forceps to 50-ml
tubes containing 5 ml PBS and glass beads. The tubes were vortexed for 2 min and sonicated for
2 min to recover spores from the disc surface. The solution was serially diluted 3 times and 1 ml
of each dilution was added to duplicate empty petri plates. The dilutions were pour-plated with
BHIT agar supplemented with C. difficile moxalactum norfloxacin (CDMN) and incubated
anaerobically for 48 h after which colonies were enumerated.
2.3 Efficacy of OH wipes in reducing C. difficile spores on stainless steel surfaces
The wiping experiments were conducted using a previously published protocol with
modification (Siani et al., 2011). Wipes (Kimberly Clark™ WypAll™ X60 Wipers) (Kimberly
Clark, Irving, TX, USA) were cut (4x4 cm) and sterilized by autoclaving. Stainless steel discs (16
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mm diameter) were attached to petri plates and inoculated with 100 ul of spore suspension
containing ~105 spores. The experiment was repeated with 100 µl of lower spore inoculations in
log increments; i.e., 104, 103 and 102. The inoculum was air-dried at room temperature for 1 h. The
treatments of 1%, 3%, and 5% OH were applied on disk surfaces and allowed to incubate for 10
min, followed by immediate wiping. A wipe was pinned to a sterile rubber stopper attached to a
stirring rod of a rotating overhead electric drill (Fig. 1). Wipes were rotated mechanically with an
electric drill for 10 s at 60 rpm with a downward weight of 500 g. The wipe was stamped on the
four quadrants of a BHIT agar plate supplemented with CDMN and 7% horse blood. The discs
were pour-plated with BHIT agar supplemented with CDMN. The plates were incubated
anaerobically for 48 h at 37°C after which bacterial colonies were enumerated.
2.4 Statistical analysis
All experiments were carried out in duplicate and the study was repeated three times. The data
were analyzed using one-way ANOVA. Differences between the means were considered
significantly different at p < 0.05.
3. Results
To investigate the effect of OH on C. difficile spore survival and recovery on stainless steel
surfaces, the inoculated discs were treated with varying concentrations of OH. The spores were
recovered from the discs after each treatment and enumerated by dilution and plating. In addition,
the residual spores on the discs after spore recovery were also determined by pour-plating the discs
in BHIT agar supplemented with CDMN. OH significantly reduced the number of spores of C.
difficile strain ATCC BAA 1870 recovered from the stainless steel discs (p < 0.05). The treatment
with 1% OH reduced spores by 1 log CFU/ml; 2%, 3% and 4% OH reduced spores by 2 log
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CFU/ml, and 5% OH reduced spores by 2.5 log CFU/ml compared to controls (Fig. 2). Similarly,
OH significantly reduced C. difficile strain ATCC BAA 1805 spores recovered from stainless steel
discs (p < 0.05). The 1% and 2% OH treatments reduced spores by 0.5 log CFU/ml; 3% and 4%
OH reduced spores by 1 log CFU/ml and 5% OH reduced spores by about 2 log CFU/ml compared
to controls (Fig. 3). In addition, there were no residual spores present on the surface of the discs
treated with OH, indicated by absence of colonies after pour-plating the discs with BHIT agar
supplemented with CDMN. However, untreated and ethanol-treated discs contained several
residual spores, as indicated by the presence of colonies after pour-plating the discs with BHIT
agar supplemented with CDMN.
In the wiping experiment stainless steel discs were inoculated with varying concentrations
of C. difficile spores in log increments. The discs were then treated with different concentrations
of OH and wiped with a dry wipe after 10 min of contact time. The sporicidal efficacy of each
treatment was expressed in log reduction by observing complete absence of spores at a particular
inoculation level. In addition, after each wiping, the wipe was stamped onto the four quadrants of
a BHIT agar plate supplemented with CDMN in order to estimate the spore survival on the wipe.
C. difficile spores were inoculated at the level of 105, 104, 103 and 102 onto the disc surface and
treated with OH at 1%, 3% and 5% levels for 10 min followed by wiping. The results indicated
that 5% OH completely inactivated spores from the discs inoculated with 104, which suggests a 4log CFU/disc reduction in C. difficile (ATCC BAA 1870) spores (Table 1). However, several
colonies appeared on discs with control treatments (untreated control and ethanol control).
Treatments with 1% OH and 3% OH resulted in a reduction of 3-log CFU/disc in spore counts
(Table 1). In addition, the agar plates stamped with wipes containing 5% OH showed a 4-log
reduction in spore counts (Table 2), whereas in 3% and 1% OH treatments, a 2 log reduction in
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spore counts was observed. However, colonies were observed in all plates in the untreated control
and ethanol control groups (Table 2).
4. Discussion
Approximately 10%–25% of hospitalized patients and 4%–20% of residents in long-term
care facilities are colonized with C. difficile (Lessa et al., 2015; Simor et al., 2002). The shedding
of spores to the hospital environment by infected individuals is the major cause of C. difficile
transmission in healthcare facilities (Hookman & Barkin, 2009). C. difficile spores are extremely
resistant to physical and chemical disinfectants, and can reside on surfaces for several months
(Brill et al., 2006; Fawley et al., 2007; Hasan et al., 2011). C. difficile has been isolated from the
rooms of infected patients in healthcare settings with a range of 2.9% to 75% (Weber et al., 2010).
Further, in healthcare environments, C. difficile contamination has been identified in 49% of rooms
occupied by CDI patients compared to 29% of rooms occupied by asymptomatic CDI carriers
suggesting shedding of C. difficile (McFarland et al., 1989; Sethi et al., 2010). In addition,
equipment shared between patients such as bed-side tables, blood pressure cuffs and other surfaces
such as floors and toilets can be contaminated with C. difficile spores, thereby serving as a potential
source for acquiring the infection (Dubberke et al., 2008). A transmission rate above 50% was
observed after healthcare workers touched hospital surfaces such as call buttons and bed rails,
exemplifying the requirement for disinfection to prevent CDI transmission (Guerrero et al., 2012).
Therefore, it is critical to disinfect hospital rooms daily with an effective and safe antimicrobial
against C. difficile spores.
Our results indicate that OH significantly reduced C. difficile (strains ATCC BAA 1870
and ATCC BAA 1805) spores on stainless steel discs compared to controls (p < 0.05) (Fig. 2 and
3). In addition, wiping with 5% OH treatment removed up to 4 log C. difficile spores from the
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stainless steel disc surface (Table 1), thereby suggesting the potential for OH to be utilized as a
surface wipe. Previously, it was reported that wiping with non-sporicidal agents alone removed
2.9 log of C. difficile spores, while wiping with a sporicidal agent yielded a greater reduction of
3.9 log (Rutala et al., 2012). However, these researchers did not determine the population of
residual spores on the wipes. The efficacy of OH for reducing spores was generally found to
increase with OH concentration, since the contact time was constant. For example, in the first
experiment, where inoculated discs were immersed with various treatments, reductions in spore
counts on discs increased with increased OH concentration, with 5% treatment leading to the
maximum decrease of ~ 2.5 log CFU/ml (Fig. 2 and 3). Similarly in the wiping study, 5% OH was
most effective, reducing the spore population by 4 log CFU/disc, followed by 3% OH with a 2 log
CFU/disc reduction (Table 1). Likewise, the residual spore population in the wipes were also
lowest in the 5% treatment, followed by 3% and 1% treatment groups (Table 2).
In conclusion, the results of this study suggest the potential use of OH as a disinfectant on
hospital stainless steel surfaces to reduce C. difficile spores. This study represents the first report
investigating the efficacy of OH for killing C. difficile spores on a surface. Although the
mechanisms behind the sporicidal effect of OH are not known, OH exerts its antimicrobial effect
against bacterial cells by binding to the negatively charged bacterial cell envelope, and disrupting
the functions of the cell (Brill et al., 2006). Octenidine hydrochloride is stable within a wide pH
range of 1.6 to 12.2, and is not sensitive to hydrolysis from light, harsh chemical or physical
conditions (Harke, 1989). Thus, the safety and stability of OH make it an ideal disinfectant for
routine use in hospitals.
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Fig. 1. The wiping apparatus to test the effect of octenidine hydrochloride wiping on C.
difficile spores inoculated on stainless steel discs.
A wipe was pinned to a sterile rubber stopper attached to a stirring rod of a rotating overhead
electric drill. Wipes were rotated mechanically with the drill for 10 s at 60 rpm with a downward
weight of 500 g. A weigh balance was placed under the drill to monitor the 500 g of weight applied.

125

Fig. 2. The effect of octenidine hydrochloride on C. difficile spores (ATCC BAA 1870)
inoculated on stainless steel discs.
The surface of each disc was inoculated with 100 ul of C. difficile spores (ATCC BAA 1870) with
1.7 x 106 spores. The discs were then subjected to treatments for 10 min including, control, ethanol
control, 1%, 2%, 3%, 4%, or 5% OH. The dilutions were pour-plated with BHIT agar
supplemented with CDMN and incubated anaerobically for 48 h after which colonies were
enumerated. * indicates treatments with significant difference at p < 0.05.
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Fig. 3. The effect of octenidine hydrochloride on C. difficile spores (ATCC BAA 1805)
inoculated on stainless steel discs.
The surface of each disc was inoculated with 100 ul of C. difficile spores (ATCC BAA 1805) with
1.7 x 106 spores. The discs were then subjected to treatments for 10 min including, control, ethanol
control, 1%, 2%, 3%, 4%, or 5% OH. The dilutions were pour-plated with BHIT agar
supplemented with CDMN and incubated anaerobically for 48 h after which colonies were
enumerated. * indicates treatments with significant difference at p < 0.05.
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Table 1. Recovery of C. difficile spores from stainless steel discs after wiping with OH.
Stainless steel discs were inoculated with 100 µl of spore solution containing concentrations of
105, 104, 103 and 102 CFU spores/disc. The treatments [untreated control, ethanol control, 1% OH,
3% OH, and 5% OH] were applied on the disk surface and allowed to act for 10 min and were
immediately wiped. The discs were pour-plated with BHIT agar supplemented with CDMN and
incubated anaerobically for 48 h at 37°C. The (+) represents the presence of C. difficile colonies
on the BHIT plate recovered from stainless steel discs.
Control

Ethanol

1% OH

3% OH

5% OH

105 CFU/disc

+

+

+

+

+

104 CFU/disc

+

+

+

No colonies

No colonies

103 CFU/disc

+

+

No colonies

No colonies

No colonies

102 CFU/disc

+

+

No colonies

No colonies

No colonies
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Table 2. Recovery of residual C. difficile spores from wipes after wiping stainless steel discs.
Stainless steel discs were inoculated with 100 µl of spore solution containing concentrations of
105, 104, 103 and 102 CFU spores/disc. The treatments [untreated control, ethanol control, 1% OH,
3% OH, and 5% OH] were applied on the disc surface and allowed to act for 10 min followed by
immediate wiping. Wipes were mechanically rotated with an electric drill for 10 s at 60 rpm with
a downward weight of 500 g. The wipe was stamped on the four quadrants of a BHIT agar plate
supplemented with CDMN and 7% horse blood and incubated anaerobically for 48 h at 37°C. The
(+) represents the presence of C. difficile colonies on the BHIT plate recovered from wipes.
Control

Ethanol

1% OH

3% OH

5% OH

105 CFU/disc

+

+

+

+

+

104 CFU/disc

+

+

+

+

No colonies

103 CFU/disc

+

+

+

+

No colonies

102 CFU/disc

+

+

No colonies

No colonies

No colonies
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Chapter VII
Aspirin reduces sporulation and spore-outgrowth in hyper-virulent Clostridium difficile in
vitro
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Abstract
Clostridium difficile is a spore-forming nosocomial pathogen that causes a serious enteric
disease in humans. Treatments that can decrease C. difficile toxin and spore production could
significantly reduce the severity, transmission and relapse of C. difficile infections (CDI). This
study investigated the efficacy of a commonly used non-steroidal anti-inflammatory drug (NSAID)
and cardio-protective medication, namely aspirin (acetylsalicylic acid), in reducing C. difficile
toxin synthesis, spore production, germination and spore outgrowth.
Two C. difficile isolates (hyper-virulent stains ATCC BAA 1805 and 1870) were grown
separately with or without sub-inhibitory concentrations (SIC) i.e. 0.05% (2.7 mM) and 0.1% (5.5
mM) of aspirin. Total viable counts (TVC) and spore counts (after heat shock at 60°C for 20 min)
were determined after 72 h of incubation. In addition, the effect of aspirin on toxin production was
determined. Real-time qPCR was performed to determine the effect of aspirin on C. difficile
sporulation genes. To determine the effect of aspirin on C. difficile germination and spore
outgrowth, C. difficile spores were grown in germination medium with or without the SIC or
minimum inhibitory concentration (MIC) of aspirin and the optical density at 600 nm was
recorded.
Aspirin SIC significantly reduced sporulation in two hyper-virulent strains of C. difficile
and down-regulated genes involved in spore production (p < 0.05). In addition, the highest SIC of
aspirin reduced spore outgrowth (p < 0.05), whereas the MIC completely inhibited outgrowth (p
< 0.05). Results suggest that aspirin could potentially be used to control transmission and relapse
of C. difficile by reducing spore production and spore outgrowth.
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1. Introduction
Clostridium difficile is a spore-forming anaerobic bacterium, which causes a serious enteric
illness in humans, predominantly in healthcare settings (Weese 2010, Stanley, Bartlett et al. 2013).
Annually in the United States, more than 500,000 cases of C. difficile infection (CDI) are reported,
costing ~ $3 billion in healthcare and treatment costs (Ghose, Kalsy et al. 2007, Lessa, Mu et al.
2015). C. difficile has the highest incidence among all nosocomial pathogens reported globally
(McDonald, Owings et al. 2006, Hookman, Barkin 2009, Stanley, Bartlett et al. 2013, Riggs, Sethi
et al. 2007). The predominant predisposing factor of C. difficile infection in humans is prolonged
antibiotic therapy (Hookman, Barkin 2009), which results in the disruption of normal enteric
microflora, thereby allowing the germination and outgrowth of C. difficile spores in the gut. C.
difficile spores germinate in the intestine in the presence of bile acid that acts as a germinant, and
colonize the colon, where vegetative cells produce toxins, leading to severe diarrhea. Further,
sporulation of vegetative cells occurs in the colon, and newly formed spores shed in the feces can
potentially contaminate hospitals and healthcare facilities leading to new infections through the
fecal-oral route (Barbut, Menuet et al. 2009). Sporulation in C. difficile is a complex process
regulated by a set of genes, including spo0A, which is the master regulator of sporulation (Saujet,
Pereira et al. 2013). Although toxins are the major virulence factors responsible for the
pathogenesis of CDI, sporulation, germination and spore outgrowth in C. difficile are critical for
transmission and relapse of the infection in humans (Sunenshine, McDonald 2006, Akerlund,
Persson et al. 2008). Relapse of infection is a major concern in CDI recovered patients, and is
observed in 20-30% of reported cases (Barbut, Richard et al. 2000, Kelly, LaMont 2008).
Therefore, it is critical to control C. difficile sporulation in the human gastrointestinal tract for
controlling CDI and its transmission.
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Acetylsalicylic acid, commonly known as aspirin, is a well-known non-steroidal antiinflammatory drug (NSAID). Aspirin is the most widely used drug in medicine (Soni 2005). The
US Preventative Services Task Force recommends a daily low dose of aspirin (≤ 30mg) for the
prevention of cardiovascular disease as a preemptive measure for recurrent cardiovascular events
(Ittaman, VanWormer et al. 2014, US Preventive Services Task Force 2009). Low dose aspirin has
been shown to reduce the aggregation of platelets, thereby preventing blood vessel obstruction and
reducing the risk of heart attack and stroke (Dippel, Van Kooten et al. 2004). Moreover, the antiinflammatory effect of aspirin has been reported to reduce colonic inflammation and decrease the
risk of colorectal cancer in long-term clinical trials (Chan, Giovannucci et al. 2005, Smith,
Hutchison et al. 2015). In addition, aspirin was identified as a factor that reduced mortality in an
observational study of adults diagnosed with CDI (Saliba, Barnett-Griness et al. 2014). However,
the mechanistic basis behind the reduced CDI mortality linked to aspirin is unknown. Therefore,
the objective of this study was to investigate the effect of aspirin on C. difficile toxin production,
spore production, spore germination and spore outgrowth.
2. Materials and Methods
2.1 Bacterial strains and culture conditions
Clostridium difficile hypervirulent strains (ATCC BAA 1805 and 1870) were grown in
brain heart infusion broth (BHI) supplemented with 5% yeast extract (Difco, Sparks, MD, USA)
at 37oC for 24 h in a Whitley A35 anaerobic workstation (Microbiology International, Frederick,
MD, USA) under a gaseous atmosphere of 80% nitrogen, 10% carbon dioxide and 10% hydrogen.
The broth cultures were sedimented by centrifugation (3600 g, 15 min, 4°C), and the pellet was
washed twice, and resuspended in sterile phosphate-buffered saline (PBS, pH 7.0), which was used
as the inoculum for this study. The bacterial populations in the cultures were determined by serial
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dilution (1:10 in PBS) and plating 0.1 ml portions of appropriate dilutions on duplicate BHI agar
and Clostridium difficile moxalactum norfloxacin (CDMN) agar (Oxoid, USA) supplemented with
5% horse blood under strict anaerobic conditions for 24 h.
2.2 Spore preparation
C. difficile spores were prepared using a previously published protocol (Sorg, Dineen
2009). Single colonies of ATCC BAA 1805 and 1870 were inoculated separately into BHI
supplemented with 5% yeast extract (BHIS), and cultured overnight at 37°C under anaerobic
conditions as before. A 150 µl aliquot of overnight culture was gently rotated to evenly distribute
the culture onto BHIS agar in six well plates and was cultured for 7 days at 37°C in an anaerobic
workstation to allow sporulation. After 7 days, spores were collected by flooding wells with 2 ml
of ice cold sterile deionized water (dH2O) with gentle pipetting and mixing. The collected spore
suspension was heat-treated at 60°C for 20 min to kill any vegetative cells and was washed five
times in sterile dH2O by centrifugation at 16,000 g for 5 min for purification. Spore suspensions
were visualized under a microscope to ensure 90% sporulation prior to storage.
2.3 Determination of MIC and SIC of aspirin against C. difficile
The MIC and SIC of aspirin (Sigma-Aldrich, St. Louis, MO, USA) was determined based
on a previously published protocol (Mooyottu, Kollanoor-Johny et al. 2014). Forty ml of BHI
supplemented with 5% yeast extract was inoculated separately with ~ 5.0 log CFU of C. difficile,
followed by the addition of 0.5 ml to 10 ml of aspirin working solution (400 mg aspirin dissolved
in 10 ml of dimethyl sulfoxide, DMSO (222 mM aspirin)) with an increment of 0.5 ml. The cultures
were incubated at 37°C for 24 h, and bacterial growth was determined by measuring the optical
density at 600 nm and by plating on BHIS agar with incubation in an anaerobic workstation. The
lowest concentration of aspirin that inhibited bacterial growth after 24 h of incubation was selected
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as its MIC, and the two highest concentrations below the MIC that did not inhibit bacterial growth
were selected as the SICs for this study. Duplicate samples were included and the experiment was
replicated three times.
2.4 Effect of aspirin on C. difficile growth and sporulation kinetics
The effect of aspirin on C. difficile growth and sporulation kinetics was determined using
a published protocol (Babakhani, Bouillaut et al. 2012). Tubes containing 40 ml of BHIS were
inoculated separately with 5.0 log CFU/ml of each C. difficile isolate (ATCC BAA 1805 and 1870)
with and without the SICs (0.05% and 0.1% w/v) of aspirin dissolved in DMSO. Separate control
tubes were included for DMSO alone and pH (adjusted to the pH of aspirin treatments using 0.1
N HCl) and were incubated anaerobically at 37oC for 72 h. Sampling was done after 72 h of
incubation for quantitation of spores (spores surviving heat shock of 60°C for 20 min) and total
viable count (TVC) by serially diluting each sample in PBS and plating in duplicate on BHIS agar
supplemented with 0.1% sodium taurocholate (Sigma Aldrich).
2.5 Effect of aspirin on C. difficile total toxin A and B
Tubes containing 40 ml of BHIS were inoculated with 5.0 log CFU/ml of each C. difficile
isolate (ATCC BAA 1805 and 1870) with and without the different concentrations of aspirin
dissolved in DMSO. As before, control tubes were included for DMSO alone and pH (adjusted to
the pH of aspirin treatments using 0.1 N HCl). The tubes were incubated anaerobically at 37 oC
for 48 h and the culture supernatant was collected at 24 h and 48 h of incubation for total toxin A
and B quantitation by ELISA. Quantification of toxin present in the culture supernatant was done
using the Wampole Tox A/B II kit (TechLabs, Inc., Blacksburg, VA, USA), as described by
Merrigan et al. (Merrigan, Venugopal et al. 2010). Purified toxin B (Sigma Aldrich) was used to
plot a standard curve for estimation of total toxin concentration. The culture supernatants were
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diluted and ELISA was performed according to manufacturer’s instructions. The optical density
was measured at 450 nm and measurements were compared with the linear range of the standard
curve to estimate total toxin concentration.
2.6 Effect of MIC and SIC of aspirin on C. difficile spore germination and outgrowth
To assess the germination of C. difficile (ATCC BAA 1805 and 1870), 100 µl suspensions
containing 5.0 log CFU spores/ml were added to the wells of a 12-well plate containing 1.9 ml of
pre-warmed (temperature), pre-reduced (exposure to anaerobic environment) BHIS broth
supplemented with 0.1% sodium taurocholate inside an anaerobic workstation. The SIC (0.1%
w/v) and MIC (0.15% w/v) of aspirin were added to the treatment wells. BHIS broth without
sodium taurocholate and dH2O were included as controls. One well with resazurin (0.1 mg/ml)
was included to indicate the maintenance of anaerobiosis within the sealed plate during reading.
The plate was sealed inside an anaerobic workstation using a sealant. The optical density was
measured at 600 nm for the spore -media mixture in each well using a Synergy plate reader (Biotek,
VT, USA) at 37°C over a 24 h time period with readings taken at 10 min intervals, and was
expressed as a percentage of the initial OD600 (t/t0). The spore germination was measured as the
initial loss of OD600 and spore outgrowth was measured by the increase in OD600 followed by spore
germination plotted against time (Allen, Babakhani et al. 2013, Paredes-Sabja, Bond et al. 2008).
2.7 Real time quantitative PCR (RT-qPCR)
To determine the effect of aspirin on C. difficile genes involved in spore production, total
RNA was isolated during the stationary phase of growth from SIC-treated and control cultures
(Blossom, McDonald 2007). The culture supernatant was separated by centrifugation at 3000 × g
for 10 min at 4°C and the bacterial pellet was immediately used for RNA extraction. Total RNA
was extracted using the Ambion RiboPure Bacteria RNA kit (Ambion Austin, TX, USA) according
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to the manufacturer's instructions, followed by DNase I digestion using Turbo DNase I (Ambion).
The cDNA was synthesized using the Bio-Rad iScript cDNA synthesis kit according to
manufacturer’s instructions (Bio-Rad, Hercules, CA, USA). The expression of genes associated
with spore production were analyzed by RT-qPCR using published primers (Babakhani, Bouillaut
et al. 2012, Saujet, Monot et al. 2011) normalized against rpoC and 16s gene expression. Twenty
μl reactions were performed in triplicate using iTaq universal SYBR Green (Bio-Rad). The relative
fold change in gene expression was calculated using the 2-ΔΔCt method (Livak, Schmittgen 2001).
2.8 Statistical analysis
All experiments had duplicate samples and the studies were repeated three times. The data
were analyzed using one-way ANOVA. Differences between the means were considered
significantly different at p < 0.05.
3. Results and Discussion
3.1 Sub-inhibitory and minimal inhibitory concentrations of aspirin
The MIC of aspirin against C. difficile was found to be 0.15% w/v. The SICs (two highest
concentrations below MIC) of aspirin were 0.05% w/v (2.7 mM) and 0.1% w/v (5.5 mM), which
did not inhibit the growth of C. difficile isolates after 24 h of incubation at 37ºC.
3.2 Effect of aspirin on C. difficile sporulation kinetics
The effect of the SICs of aspirin on C. difficile spore production is depicted in Fig. 1. In
isolate BAA 1805, in the presence of aspirin at 0.1% and 0.05%, there was a significant decrease
in spore count after 72 h of incubation compared to controls (p < 0.05) (Fig. 1A). Aspirin at 0.1%
and 0.05% resulted in ~ 3.0 log CFU/ml and 2.0 log CFU/ml reduction in spore counts,
respectively. However, spore count of all control groups (no aspirin control, pH control and
DMSO control) were not significantly different. In addition, the total viable count (plated without
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heat treatment) in aspirin-treated and control samples were not significantly different (p > 0.05).
Similar results were observed with isolate BAA 1870, where addition of 0.1% and 0.05% aspirin
brought about 3.5 log CFU/ml and 2.0 log CFU/ml reduction in spore counts, respectively (Fig.
1B). No differences in spore counts were observed among the control samples.
3.3 Effect of aspirin on C. difficile spore germination and outgrowth
The effect of SIC (0.1%) and MIC (0.15%) of aspirin on spore germination and outgrowth
over a 24 h time period was determined. In control wells (no aspirin control, DMSO control and
pH control), spore outgrowth was observed as indicated by an increase in the absorbance starting
at 12 h, with continued increase over the 24 h duration (Fig. 2A and 2B). Aspirin at 0.1% delayed
C. difficile spore outgrowth by 4 h, and significantly reduced spore germination compared to
controls in both isolates (p < 0.05). On the other hand, aspirin at 0.15% was more effective in
inhibiting C. difficile spore outgrowth, with only a slight increase in absorbance observed at 22 h
of incubation for both isolates (p < 0.05) (Fig. 2A and 2B ).
3.4 Effect of aspirin on C. difficile toxin production
The effect of aspirin on toxin production was investigated by collecting the supernatant at
24 and 48 h and quantifying total toxin A and B by ELISA. Results revealed that aspirin did not
significantly affect the toxin production compared to controls at both 24 and 48 h of incubation (p
> 0.05) (data not shown).
3.5 Effect of aspirin on C. difficile spore production genes
The effect of the SIC of aspirin on the expression of genes critical for sporulation in C.
difficile is shown in Fig. 3A and 3B. Transcriptional analysis of C. difficile sporulation associated
genes by RT-qPCR showed that aspirin significantly down-regulated (p < 0.05) the expression of
spo0A by 8 fold in BAA 1805 and 15 fold in BAA 1870, and spoIIA by 25 fold and 35 fold in
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BAA 1805 and BAA 1870, respectively. In addition, the expression of spoIIR was decreased by
72 and 13 fold for BAA 1805 and 1870, and that of spoIIID by 69 fold and 10 fold in C. difficile
BAA 1805 and 1870, respectively.
4. Discussion
C. difficile has the highest incidence as a nosocomial pathogen, and recent surveillance
data have shown that C. difficile has surpassed methicillin-resistant Staphylococcus aureus as the
most frequently acquired hospital infection (Miller, Chen et al. 2010). Sporulation of C. difficile
is a crucial event in CDI transmission, where spore germination and outgrowth are necessary for
establishing infection in a susceptible patient. C. difficile sporulation occurs at the time of egestion
resulting in fecal shedding of spores which can subsequently contaminate the environment. In
addition, C. difficile spores survive on hospital surfaces due to their resistance to most physical
and chemical disinfectants used in hospital settings (Setlow 2006). Clostridium difficile spores
reach the gut of the affected individual through the fecal-oral route, germinate and outgrow to form
vegetative cells which colonize the large intestine and produce potent toxins that are responsible
for C. difficile associated diarrhea. Sporulation is an important virulence factor in C. difficile
pathogenesis and transmission and agents that can reduce C. difficile sporulation and outgrowth
could potentially reduce C. difficile infection in susceptible individuals (Johnson 2009, Maroo,
Lamont 2006). Our data suggest that aspirin, a commonly used non-steroidal anti-inflammatory
drug, which is also routinely prescribed to heart patients due to its anti-thrombotic cardio protective
effect, can significantly reduce C. difficile spore production and spore outgrowth in vitro. This
finding could potentially explain the clinical observation of reduced CDI morbidity in patients
taking daily low-dose aspirin (Saliba, Barnett-Griness et al. 2014).
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Our data demonstrate that SICs of aspirin significantly reduced spore production by C.
difficile after 72 h of incubation (p < 0.05). Aspirin readily dissociates to salicylic acid in the gut,
which can reduce the pH of the gut environment. In our experiments, the pH of BHI broth was
7.09, which decreased to 6.78 with the addition of aspirin. Hence, we included a pH control in the
experiment in order to rule out the pH effect of aspirin in reducing C. difficile sporulation.
However, spore production in pH control did not differ significantly from the negative control,
indicating that the observed reduction in spore production was not due to the reduced acidity effect
of aspirin. Similarly, a diluent control (DMSO) was also included, where spore production did not
differ significantly from the negative control. However, a reduction in sporulation was observed
in aspirin-treated samples by dilution and plating method (p < 0.05). In addition, our gene
expression studies indicated that aspirin significantly down-regulated important genes responsible
for C. difficile sporulation. Moreover, the germination experiments showed that the SIC of aspirin
significantly reduced C. difficile spore outgrowth compared to controls (p < 0.05). More strikingly,
aspirin at the MIC almost completely inhibited C. difficile spore outgrowth. These results suggest
that vegetative cells from newly germinated spores are more sensitive to aspirin compared to
vegetative C. difficile cells grown in broth culture. Interestingly, the SICs of aspirin did not
increase toxin production (data not shown) as is typically observed with the use of antimicrobials
against C. difficile such as antibiotics, vancomycin and metronidazole (Gerber, Walch et al. 2008).
The anti-inflammatory action of aspirin in humans and animals is well studied. Aspirin
inhibits cyclooxygenase (COX) enzymes in the arachidonic acid pathway, which are required for
the synthesis of pro-inflammatory cytokines such as prostaglandins. (Vane, Botting 2003).
However, studies on the effect of aspirin on bacteria and bacterial virulence factors are very
limited. Aspirin has been shown to exert antibacterial properties against Gram-negative bacteria
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such as Brucella spp. and Helicobacter pylori by downregulation of outer membrane protein
expression (Wang, Wong et al. 2003, Munoz-Criado, Muñoz-Bellido et al. 1996). Similarly, the
antimicrobial effect of aspirin against Staphylococcus aureus by modulation of its virulence genes
has also been reported (Kupferwasser, Yeaman et al. 2003). In our study, we observed a
downregulation of C. difficile sporulation genes in the presence of aspirin in vitro. Nonetheless,
taking into account the pathogenesis of CDI, an anti-inflammatory effect of aspirin could be an
added advantage in CDI patients in reducing severe colitis symptoms.
Our results indicate preventive and therapeutic potential of aspirin in controlling C. difficile
infection. Aspirin significantly reduced C. difficile spore production besides decreasing the
outgrowth of C. difficile spores, but did not increase toxin production compared to controls. These
findings collectively suggest the potential use of aspirin to control CDI in humans. However,
follow up in vivo and clinical validations are required to confirm this.
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Fig 1. Effect of SICs of aspirin (0.5 mg/l and 1.0 mg/l) on C. difficile BAA 1805 (1A) and 1870
(1B).
Growth and sporulation kinetics by quantitation of spores (survivors of incubation at 60°C for 20
min) and total viable count (TVC). * Treatments significantly differed from the respective controls
(p < 0.05).
(A) C. difficile BAA 1805
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(B) C. difficile BAA 1870
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Fig 2. Effect of aspirin on germination and outgrowth of C. difficile BAA 1805 (A) and 1870
(B) spores.
Bacterial pellet was harvested at 24 h for RNA isolation and RT-qPCR was done for spore
production genes. * Treatments significantly differed from the controls (p < 0.05).
(A) C. difficile ATCC BAA 1805
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(B) C. difficile ATCC BAA 1870
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Fig 3. Effect of SIC of aspirin (1.0mg/l) on C. difficile ATCC BAA 1805 (A) and 1870 (B)
sporulation regulatory genes.
The spore germination was measured as the initial loss of OD600 and spore outgrowth was
measured by recording the increase in OD600 followed by spore germination. * Treatments
significantly differed from the controls (p < 0.05).
(A) C. difficile ATCC BAA 1805
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(B) C. difficile ATCC BAA 1870
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Chapter VIII
Summary
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Clostridium difficile causes a serious toxin-mediated infection in humans, primarily in
nosocomial settings. The production of toxins is one of the most important virulence factors in C.
difficile, however, sporulation, germination and spore outgrowth play a vital role in the
transmission and relapse of C. difficile infection (CDI). Relapse of infection is a major concern in
CDI patients, and is observed in 20-25% of cases. Spores can be transferred by the fecal-oral route,
therefore, it is critical to control sporulation, germination and spore outgrowth in order to control
transmission.
Hospital surfaces have been shown to be frequently contaminated with C. difficile spores,
and can remain contaminated for an extended period, thereby serving as a source of infection. C.
difficile spores are resistant to most commonly used disinfectants such as sodium hypochlorite.
Therefore, it is critical to reduce control spore survival on surfaces. A novel disinfectant known as
octenidine hydrochloride (OH) was investigated for its efficacy to decrease C. difficile spores on
stainless steel surface. Results revealed that direct application of OH (5%) and wiping with OH
reduced spore numbers on stainless steel surface (p < 0.05).
Transmission and relapse of CDI can also be reduced by controlling sporulation in the gut.
Sporulation in C. difficile is regulated by spoOA, which is the master regulator of sporulation.
Aspirin, a widely used non-steroidal anti-inflammatory drug was reported to reduce mortality in
adults with CDI. This led to our investigation of aspirin at its sub-inhibitory concentration (SIC)
and minimal inhibitory concentration (MIC) for reducing C. difficile sporulation, spore
germination and spore outgrowth in vitro. The SIC of aspirin significantly reduced sporulation of
C. difficile and down-regulated critical genes involved in spore production (p < 0.05). Also, the
SIC of aspirin reduced spore outgrowth and the MIC completely inhibited outgrowth (p < 0.05).
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A recent trend has identified increased C. difficile infections in community settings,
totaling 32% of all cases. Community-associated infections occur in low risk patients who are
comparably younger than traditional patients, and have no recent history of hospitalization or long
term antibiotic treatment. In addition, C. difficile spores have been isolated from wild animals,
food animals, animal-derived foods and the environment. C. difficile spores have also been isolated
from fresh produce, but limited prevalence studies exist in the US. In our study, a 23% prevalence
rate in REL (35/150) procured from various retail stores in Connecticut was observed.
Additionally, C. difficile spores in REL packaged under MAP conditions (2% O2, 5% CO2 and
93% N2) remained viable for 10 days of refrigerated storage.
Clostridium difficile spores were inoculated in ground beef and were subjected to chilling
storage at 4°C for a week, freezer storage at -18°C for 12 weeks or cooking to the USDA
recommended internal temperature of 71.1°C. At inoculation levels of 3 log CFU/g and 5 log
CFU/g, C. difficile spores remained the same during chilling and freezer storage (p > 0.05).
Cooking ground beef to the USDA recommended internal temperature of 71.1°C decreased spores
by 1 log CFU/g for both inoculation level (p < 0.05). The results indicated that C. difficile spores
can survive chilling, freezing and the USDA recommended cooking temperature for ground beef.
Similarly, C. difficile spores remained viable in fermented summer sausage with low pH of 5.0 for
90 days of storage, and the survival was not significantly different from unfermented control
sausages (p > 0.05). Therefore, if C. difficile spores were present in a commercial ground beef
product or a fermented summer sausage product, they could survive typical storage and cooking
conditions.
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